Peptide	O
vaccination	O
can	O
lead	O
to	O
enhanced	O
tumor	O
growth	O
through	O
specific	O
T-cell	O
tolerance	O
induction	O
.	O

Vaccination	O
with	O
synthetic	O
peptides	O
representing	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
can	O
lead	O
to	O
a	O
protective	O
CTL-mediated	O
immunity	O
against	O
tumors	O
or	O
viruses	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	B-DNA
adenovirus	I-DNA
type	I-DNA
5	I-DNA
E1A-region	I-DNA
(	O
Ad5E1A234-243	B-DNA
)	O
,	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor-eradicating	B-cell_type
CTL	I-cell_type
,	O
enhances	O
rather	O
than	O
inhibits	O
the	O
growth	O
of	O
Ad5E1A-expressing	O
tumors	O
.	O

This	O
adverse	O
effect	O
of	O
peptide	O
vaccination	O
was	O
rapidly	O
evoked	O
,	O
required	O
low	O
doses	O
of	O
peptide	O
(	O
10	O
micrograms	O
)	O
,	O
and	O
was	O
achieved	O
by	O
a	O
mode	O
of	O
peptide	O
delivery	O
that	O
induces	O
protective	O
T-cell-mediated	O
immunity	O
in	O
other	O
models	O
.	O

Ad5E1A	B-protein
-specific	O
CTL	O
activity	O
could	O
no	O
longer	O
be	O
isolated	O
from	O
mice	O
after	O
injection	O
of	O
Ad5E1A-peptide	O
,	O
indicating	O
that	O
tolerization	O
of	O
Ad5E1A	B-protein
-specific	O
CTL	O
activity	O
causes	O
the	O
enhanced	O
tumor	O
outgrowth	O
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	B-protein
,	O
induced	O
Ad5E1A	B-protein
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	B-protein
-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti-tumor	O
CTL	O
responses	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide-based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T-cell-mediated	O
autoimmune	O
diseases	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
pp	NULL
.	NULL

7855-7860	NULL
,	NULL
July	NULL
1996	NULL
Immunology	NULL
Peptide	NULL
vaccination	NULL
can	NULL
lead	NULL
to	NULL
enhanced	NULL
tumor	NULL
growth	NULL
through	NULL
specific	NULL
T-cell	NULL
tolerance	NULL
induction	NULL
RENE	NULL
E.	NULL
M.	NULL
RIENK	NULL
OFFRINGA*	NULL
,	NULL
Ria	NULL
J.	NULL
J.	NULL
BLom*	NULL
,	NULL
CORNELIS	NULL
J.	NULL
M.	NULL
MELIEF*	NULL
,	NULL
AND	NULL
W.	NULL
MARTIN	NULL
Kast**	NULL
*Department	NULL
of	NULL
Immunohematology	NULL
and	NULL
Blood	NULL
Bank	NULL
,	NULL
University	NULL
Hospital	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
9600	NULL
,	NULL
2300	NULL
RC	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
;	NULL
and	NULL
*Tumor	NULL
Immunology	NULL
Program	NULL
,	NULL
Loyola	NULL
University	NULL
Cancer	NULL
Center	NULL
,	NULL
2160	NULL
South	NULL
First	NULL
Avenue	NULL
,	NULL
Maywood	NULL
,	NULL
IL	NULL
60153	NULL
Communicated	NULL
by	NULL
J.	NULL
J.	NULL
van	NULL
Rood	NULL
,	NULL
Leiden	NULL
University	NULL
Hospital	NULL
,	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
,	NULL
April	NULL
8	NULL
,	NULL
1996	NULL
(	NULL
received	NULL
for	NULL
review	NULL
October	NULL
2	NULL
,	NULL
1995	NULL
)	NULL
ABSTRACT	NULL
Vaccination	NULL
with	NULL
synthetic	NULL
peptides	NULL
representing	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
epitopes	NULL
can	NULL
lead	NULL
to	NULL
a	NULL
protective	NULL
CTL-mediated	NULL
immunity	NULL
against	NULL
tumors	NULL
or	NULL
viruses	NULL
.	NULL

We	NULL
now	NULL
report	NULL
that	NULL
vaccination	NULL
with	NULL
a	NULL
CTL	NULL
epitope	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
adenovirus	NULL
type	NULL
5	NULL
E1l1A-region	NULL
(	NULL
AdSE1A	NULL
;	NULL
34-243	NULL
)	NULL
,	NULL
which	NULL
can	NULL
serve	NULL
as	NULL
a	NULL
target	NULL
for	NULL
tumor-eradicating	NULL
CTL	NULL
,	NULL
enhances	NULL
rather	NULL
than	NULL
inhibits	NULL
the	NULL
growth	NULL
of	NULL
Ad5E1A-expressing	NULL
tumors	NULL
.	NULL

This	NULL
adverse	NULL
effect	NULL
of	NULL
peptide	NULL
vaccination	NULL
was	NULL
rapidly	NULL
evoked	NULL
,	NULL
required	NULL
low	NULL
doses	NULL
of	NULL
peptide	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
was	NULL
achieved	NULL
by	NULL
a	NULL
mode	NULL
of	NULL
peptide	NULL
delivery	NULL
that	NULL
induces	NULL
protective	NULL
T-cell-mediated	NULL
immunity	NULL
in	NULL
other	NULL
models	NULL
.	NULL

AdS5E1A-specific	NULL
CTL	NULL
activity	NULL
could	NULL
no	NULL
longer	NULL
be	NULL
isolated	NULL
from	NULL
mice	NULL
after	NULL
injection	NULL
of	NULL
Ad5E1A-peptide	NULL
,	NULL
indicating	NULL
that	NULL
tolerization	NULL
of	NULL
AdSE1A-specific	NULL
CTL	NULL
activity	NULL
causes	NULL
the	NULL
enhanced	NULL
tumor	NULL
outgrowth	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
peptide	NULL
vaccination	NULL
,	NULL
immunization	NULL
with	NULL
adenovirus	NULL
,	NULL
expressing	NULL
Ad5E1A	NULL
,	NULL
induced	NULL
AdSE1A-specific	NULL
immunity	NULL
and	NULL
prevented	NULL
the	NULL
outgrowth	NULL
of	NULL
AdSE1A-expressing	NULL
tumors	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
immunization	NULL
with	NULL
synthetic	NULL
peptides	NULL
can	NULL
lead	NULL
to	NULL
the	NULL
elimination	NULL
of	NULL
anti-tumor	NULL
CTL	NULL
responses	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
important	NULL
for	NULL
the	NULL
design	NULL
of	NULL
safe	NULL
peptide-based	NULL
vaccines	NULL
against	NULL
tumors	NULL
,	NULL
allogeneic	NULL
organ	NULL
transplants	NULL
,	NULL
and	NULL
T-cell-mediated	NULL
autoimmune	NULL
diseases	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTL	NULL
)	NULL
can	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
defense	NULL
against	NULL
experimental	NULL
and	NULL
human	NULL
malignancies	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

CTL	NULL
recognize	NULL
small	NULL
antigenic	NULL
peptide	NULL
fragments	NULL
in	NULL
the	NULL
context	NULL
of	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
molecules	NULL
(	NULL
3	NULL
)	NULL
.	NULL

These	NULL
peptides	NULL
are	NULL
mostly	NULL
generated	NULL
from	NULL
endogenously	NULL
synthesized	NULL
proteins	NULL
.	NULL

Vaccination	NULL
with	NULL
synthetic	NULL
peptides	NULL
corresponding	NULL
to	NULL
CTL	NULL
epitopes	NULL
can	NULL
induce	NULL
protective	NULL
CTL-mediated	NULL
immunity	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
model	NULL
systems	NULL
(	NULL
4	NULL
)	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
immunization	NULL
of	NULL
mice	NULL
with	NULL
synthetic	NULL
peptides	NULL
deduced	NULL
from	NULL
proteins	NULL
of	NULL
either	NULL
Sendai	NULL
virus	NULL
or	NULL
lymphocytic	NULL
choriomeningitis	NULL
virus	NULL
(	NULL
LCMV	NULL
)	NULL
led	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
protective	NULL
immunity	NULL
against	NULL
a	NULL
subsequent	NULL
challenge	NULL
of	NULL
respectively	NULL
Sendai	NULL
virus	NULL
or	NULL
LCMV	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

In	NULL
tumor	NULL
models	NULL
,	NULL
protective	NULL
immunity	NULL
was	NULL
established	NULL
by	NULL
immunization	NULL
with	NULL
tumor-specific	NULL
synthetic	NULL
peptides	NULL
.	NULL

Immunization	NULL
with	NULL
a	NULL
peptide	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
papillomavi-rus	NULL
type	NULL
16	NULL
(	NULL
HPV16	NULL
)	NULL
led	NULL
to	NULL
the	NULL
protection	NULL
against	NULL
a	NULL
lethal	NULL
dose	NULL
of	NULL
HPV16-transformed	NULL
tumor	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
,	NULL
and	NULL
vaccination	NULL
with	NULL
a	NULL
peptide	NULL
encompassing	NULL
a	NULL
CTL	NULL
epitope	NULL
derived	NULL
from	NULL
chicken	NULL
ovalbumin	NULL
led	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
protective	NULL
immunity	NULL
against	NULL
a	NULL
thymoma	NULL
transfected	NULL
with	NULL
the	NULL
cDNA	NULL
of	NULL
chicken	NULL
ovalbumin	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
approach	NULL
of	NULL
using	NULL
synthetic	NULL
peptide	NULL
CTL	NULL
epitopes	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
CTL	NULL
responses	NULL
is	NULL
now	NULL
being	NULL
applied	NULL
in	NULL
human	NULL
beings	NULL
.	NULL

Peptides	NULL
encoded	NULL
by	NULL
the	NULL
HPV16	NULL
early	NULL
region	NULL
6	NULL
and	NULL
7	NULL
(	NULL
E6	NULL
and	NULL
7	NULL
)	NULL
oncogenes	NULL
that	NULL
are	NULL
immunogenic	NULL
to	NULL
human	NULL
CTL	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
10	NULL
)	NULL
and	NULL
are	NULL
currently	NULL
employed	NULL
at	NULL
our	NULL
hospital	NULL
in	NULL
a	NULL
phase	NULL
I/II	NULL
peptide	NULL
vaccination	NULL
study	NULL
.	NULL

Vaccination	NULL
of	NULL
healthy	NULL
volunteers	NULL
with	NULL
the	NULL
hepatitis	NULL
B	NULL
core	NULL
antigen	NULL
peptide	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7855	NULL
18-27	NULL
linked	NULL
to	NULL
a	NULL
T-helper	NULL
epitope	NULL
and	NULL
two	NULL
palmitic	NULL
acid	NULL
molecules	NULL
induced	NULL
a	NULL
hepatitis	NULL
B	NULL
core	NULL
antigen	NULL
peptide-specific	NULL
CTL	NULL
response	NULL
cross-reactive	NULL
.	NULL

on	NULL
virus-infected	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

While	NULL
these	NULL
results	NULL
provide	NULL
the	NULL
basis	NULL
for	NULL
the	NULL
development	NULL
of	NULL
peptide-based	NULL
prophylactic	NULL
and	NULL
therapeutic	NULL
anti-tumor	NULL
vaccines	NULL
,	NULL
vaccination	NULL
with	NULL
synthetic	NULL
peptides	NULL
may	NULL
also	NULL
lead	NULL
to	NULL
T	NULL
cell	NULL
unresponsiveness	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

At	NULL
least	NULL
three	NULL
repetitive	NULL
intra-peritoneal	NULL
(	NULL
i.p	NULL
.	NULL
)	NULL

immunizations	NULL
with	NULL
a	NULL
relatively	NULL
high	NULL
dose	NULL
(	NULL
100	NULL
ug/mouse	NULL
)	NULL
of	NULL
synthetic	NULL
peptide	NULL
deduced	NULL
from	NULL
the	NULL
glycoprotein	NULL
of	NULL
LCMV	NULL
induced	NULL
specific	NULL
T-cell	NULL
tolerance	NULL
,	NULL
and	NULL
this	NULL
mode	NULL
of	NULL
peptide	NULL
delivery	NULL
prevented	NULL
the	NULL
induction	NULL
of	NULL
diabetes	NULL
by	NULL
infection	NULL
with	NULL
LCMV	NULL
in	NULL
a	NULL
transgenic	NULL
mouse	NULL
model	NULL
in	NULL
which	NULL
LCMV	NULL
glycoprotein	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
B	NULL
islet	NULL
cells	NULL
of	NULL
the	NULL
pancreas	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Apparently	NULL
,	NULL
there	NULL
is	NULL
a	NULL
balance	NULL
between	NULL
induction	NULL
of	NULL
T-cell	NULL
responses	NULL
and	NULL
tolerization	NULL
by	NULL
injection	NULL
of	NULL
antigenic	NULL
peptides	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
outcome	NULL
of	NULL
peptide	NULL
vaccination	NULL
could	NULL
have	NULL
a	NULL
strong	NULL
impact	NULL
on	NULL
the	NULL
design	NULL
,	NULL
delivery	NULL
,	NULL
and	NULL
development	NULL
of	NULL
peptide-based	NULL
anti-tumor	NULL
vaccines	NULL
,	NULL
but	NULL
will	NULL
also	NULL
have	NULL
implications	NULL
for	NULL
vaccination	NULL
strategies	NULL
against	NULL
T-cell-mediated	NULL
autoimmune	NULL
diseases	NULL
and	NULL
other	NULL
harmful	NULL
T-cell-mediated	NULL
immune	NULL
destructions	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
we	NULL
show	NULL
that	NULL
a	NULL
single	NULL
vaccination	NULL
with	NULL
a	NULL
low	NULL
dose	NULL
of	NULL
a	NULL
subcutaneously	NULL
(	NULL
s.c.	NULL
)	NULL
given	NULL
peptide	NULL
comprising	NULL
a	NULL
CTL-epitope	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
adenovirus	NULL
type	NULL
5	NULL
early	NULL
region	NULL
1A	NULL
(	NULL
Ad5E1A	NULL
)	NULL
oncogene	NULL
promotes	NULL
rather	NULL
than	NULL
suppresses	NULL
the	NULL
outgrowth	NULL
of	NULL
AdSE1A-expressing	NULL
tumor	NULL
cells	NULL
in	NULL
normal	NULL
immunocompetent	NULL
mice	NULL
.	NULL

The	NULL
inhibitory	NULL
effects	NULL
of	NULL
peptide	NULL
vaccination	NULL
were	NULL
also	NULL
noted	NULL
on	NULL
adoptively	NULL
transferred	NULL
AdSE1A-specific	NULL
CTL	NULL
clones	NULL
and	NULL
in	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
transgenic	NULL
mice	NULL
.	NULL

The	NULL
implications	NULL
of	NULL
these	NULL
findings	NULL
for	NULL
the	NULL
development	NULL
of	NULL
peptide-based	NULL
intervention	NULL
protocols	NULL
against	NULL
T-cell-mediated	NULL
autoimmune	NULL
diseases	NULL
,	NULL
allogeneic	NULL
organ	NULL
transplants	NULL
,	NULL
viral	NULL
infections	NULL
,	NULL
and	NULL
malignancies	NULL
are	NULL
discussed	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Mice	NULL
.	NULL

C57BL/6	NULL
(	NULL
B6	NULL
Kh	NULL
,	NULL
H-2	NULL
``	NULL
)	NULL
mice	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Netherlands	NULL
Cancer	NULL
Institute	NULL
(	NULL
Amsterdam	NULL
)	NULL
and	NULL
C57BL/6	NULL
nu/nu	NULL
(	NULL
B6	NULL
nude	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Bomholtgard	NULL
(	NULL
Ry	NULL
,	NULL
Denmark	NULL
)	NULL
.	NULL

The	NULL
TCR	NULL
transgenic	NULL
mice	NULL
express	NULL
the	NULL
TCR-a	NULL
and	NULL
-B	NULL
chains	NULL
derived	NULL
from	NULL
the	NULL
H-2D®-restricted	NULL
,	NULL
AdSE1Aq34-243-specific	NULL
CTL	NULL
clone	NULL
5	NULL
(	NULL
14	NULL
)	NULL
.	NULL

This	NULL
T	NULL
cell	NULL
uses	NULL
rearranged	NULL
Val6	NULL
and	NULL
VB1	NULL
TCR	NULL
chains	NULL
.	NULL

The	NULL
cDNAs	NULL
encoding	NULL
the	NULL
complete	NULL
a	NULL
and	NULL
B	NULL
chains	NULL
were	NULL
inserted	NULL
into	NULL
an	NULL
expression	NULL
construct	NULL
based	NULL
on	NULL
genomic	NULL
sequences	NULL
of	NULL
the	NULL
human	NULL
CD2	NULL
gene	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
transgenes	NULL
were	NULL
coninjected	NULL
into	NULL
blastocysts	NULL
of	NULL
C57BL/6	NULL
(	NULL
B6	NULL
Kh	NULL
)	NULL
mice	NULL
.	NULL

Cell	NULL
Lines	NULL
and	NULL
Culture	NULL
Conditions	NULL
.	NULL

Cells	NULL
expressing	NULL
AdSE1A	NULL
and	NULL
EJras	NULL
(	NULL
AR-cell	NULL
lines	NULL
)	NULL
were	NULL
generated	NULL
by	NULL
trans-fection	NULL
with	NULL
pAdSE1A	NULL
(	NULL
Psfl	NULL
)	NULL
(	NULL
16	NULL
)	NULL
,	NULL
pEJras	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
pTK-neo	NULL
Abbreviations	NULL
:	NULL
AdSE1	NULL
,	NULL
adenovirus	NULL
type	NULL
5	NULL
early	NULL
region	NULL
1	NULL
;	NULL
CFA	NULL
,	NULL
complete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
;	NULL
CTL	NULL
,	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
;	NULL
HPV	NULL
,	NULL
human	NULL
papillomavirus	NULL
;	NULL
IFA	NULL
,	NULL
incomplete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
IL-2	NULL
,	NULL
recombinant	NULL
IL-2	NULL
;	NULL
LCMV	NULL
,	NULL
lymphocytic	NULL
choriomeningitis	NULL
virus	NULL
;	NULL
TCR	NULL
,	NULL
T-cell	NULL
receptor	NULL
.	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

7856	NULL
Immunology	NULL
:	NULL
Toes	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
AdSE1A	NULL
and	NULL
EJras	NULL
gene	NULL
products	NULL
was	NULL
confirmed	NULL
both	NULL
at	NULL
the	NULL
mRNA	NULL
and	NULL
protein	NULL
level	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
other	NULL
cell	NULL
lines	NULL
used	NULL
were	NULL
generated	NULL
as	NULL
described	NULL
(	NULL
14	NULL
,	NULL
18	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
maintained	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
7	NULL
,	NULL
14	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Peptides	NULL
.	NULL

Peptides	NULL
were	NULL
generated	NULL
by	NULL
solid	NULL
phase	NULL
strategies	NULL
on	NULL
a	NULL
ABIMED	NULL
422	NULL
synthesizer	NULL
(	NULL
ABIMED	NULL
,	NULL
Langenfeld	NULL
,	NULL
Ger-many	NULL
)	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Peptides	NULL
were	NULL
stored	NULL
dry	NULL
at	NULL
-70°C	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
peptides	NULL
was	NULL
determined	NULL
by	NULL
analytical	NULL
phase	NULL
HPLC	NULL
using	NULL
water-acetonitrile	NULL
gradient	NULL
containing	NULL
0.1	NULL
%	NULL
tri-fluoroacetic	NULL
acid	NULL
(	NULL
TFA	NULL
)	NULL
and	NULL
proved	NULL
to	NULL
be	NULL
at	NULL
least	NULL
85	NULL
%	NULL
(	NULL
UV	NULL
,	NULL
214	NULL
nm	NULL
)	NULL
.	NULL

The	NULL
integrity	NULL
of	NULL
the	NULL
peptides	NULL
was	NULL
determined	NULL
by	NULL
laser	NULL
desorption	NULL
time-of-flight	NULL
mass	NULL
spectrometry	NULL
(	NULL
TOF-MALDI	NULL
)	NULL
on	NULL
a	NULL
lasermat	NULL
mass	NULL
spectrometer	NULL
(	NULL
Finnigan-MAT	NULL
,	NULL
Herts	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

About	NULL
5	NULL
pmol	NULL
of	NULL
the	NULL
peptide	NULL
in	NULL
0.5	NULL
ul	NULL
water/acetonitrile	NULL
containing	NULL
0.1	NULL
%	NULL
TFA	NULL
was	NULL
mixed	NULL
with	NULL
0.5	NULL
ul	NULL
of	NULL
matrix	NULL
solution	NULL
[	NULL
ACH	NULL
;	NULL
10	NULL
mg/ml	NULL
in	NULL
acetonitrile/water	NULL
,	NULL
60/40	NULL
(	NULL
vol/vol	NULL
)	NULL
containing	NULL
0.1	NULL
%	NULL
TFA	NULL
)	NULL
and	NULL
applied	NULL
to	NULL
the	NULL
instrument	NULL
.	NULL

Calibration	NULL
was	NULL
performed	NULL
with	NULL
peptides	NULL
of	NULL
known	NULL
molecular	NULL
mass	NULL
.	NULL

Peptide	NULL
Immunization	NULL
and	NULL
Challenge	NULL
with	NULL
AdSEIA	NULL
+	NULL
ras	NULL
Transformed	NULL
Tumor	NULL
Cells	NULL
.	NULL

Peptide	NULL
immunizations	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Peptides	NULL
dissolved	NULL
in	NULL
100	NULL
l	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
were	NULL
extensively	NULL
mixed	NULL
with	NULL
100	NULL
ul	NULL
incomplete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
(	NULL
IFA	NULL
)	NULL
and	NULL
0.5	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
.	NULL

The	NULL
200	NULL
pl	NULL
mixture	NULL
was	NULL
s.c.	NULL
injected	NULL
in	NULL
B6	NULL
mice	NULL
.	NULL

Two	NULL
weeks	NULL
later	NULL
mice	NULL
were	NULL
challenged	NULL
with	NULL
10	NULL
``	NULL
AdSE1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
(	NULL
clone	NULL
AR	NULL
6	NULL
)	NULL
or	NULL
0.5	NULL
x	NULL
10°	NULL
HPV16-transformed	NULL
tumor	NULL
cells	NULL
(	NULL
clone	NULL
HPVC3	NULL
)	NULL
s.c.	NULL
in	NULL
300	NULL
pul	NULL
PBS	NULL
.	NULL

Limiting	NULL
Dilution	NULL
.	NULL

CTL	NULL
clone	NULL
5	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
)	NULL
(	NULL
14	NULL
)	NULL
was	NULL
administered	NULL
intravenously	NULL
in	NULL
normal	NULL
immunocompetent	NULL
mice	NULL
.	NULL

Three	NULL
days	NULL
later	NULL
100	NULL
ug	NULL
of	NULL
the	NULL
AdS5E1A-encoded	NULL
CTL	NULL
epitope	NULL
AdSE1A	NULL
;	NULL
34-243	NULL
(	NULL
sequence	NULL
,	NULL
Ser-Gly-Pro-Ser-Asn-Thr-Pro-Pro-Glu-lle	NULL
)	NULL
or	NULL
the	NULL
AdSE1Bis2-zmo-encoded	NULL
(	NULL
control	NULL
)	NULL
CTL	NULL
epitope	NULL
(	NULL
sequence	NULL
,	NULL
Val-Asn-Ile-Arg-Asn-lle-Cys-Cys-Tyr-lle	NULL
)	NULL
(	NULL
18	NULL
)	NULL
in	NULL
PBS	NULL
was	NULL
mixed	NULL
with	NULL
IFA	NULL
plus	NULL
0.5	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
BSA	NULL
and	NULL
s.c.	NULL
injected	NULL
.	NULL

Six	NULL
days	NULL
later	NULL
spleen	NULL
cells	NULL
of	NULL
these	NULL
animals	NULL
were	NULL
plated	NULL
out	NULL
in	NULL
a	NULL
limiting	NULL
dilution	NULL
assay	NULL
.	NULL

Twenty-four	NULL
replicate	NULL
microcultures	NULL
were	NULL
set	NULL
up	NULL
per	NULL
serial	NULL
dilution	NULL
of	NULL
responder	NULL
spleen	NULL
cells	NULL
and	NULL
5	NULL
X	NULL
10°	NULL
irradiated	NULL
(	NULL
25	NULL
Gy	NULL
)	NULL
inter-feron-y	NULL
(	NULL
2	NULL
days	NULL
,	NULL
10	NULL
units/ml	NULL
)	NULL
AdSEl-transformed	NULL
cells	NULL
in	NULL
U-bottomed	NULL
tissue	NULL
culture	NULL
plates	NULL
.	NULL

After	NULL
7	NULL
days	NULL
of	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
Cetus	NULL
Units	NULL
of	NULL
recombinant	NULL
interleukin	NULL
2	NULL
(	NULL
rIL-2	NULL
)	NULL
the	NULL
microcultures	NULL
were	NULL
split	NULL
into	NULL
three	NULL
and	NULL
tested	NULL
in	NULL
an	NULL
Europium-	NULL
(	NULL
Eu®*	NULL
)	NULL
release	NULL
assay	NULL
(	NULL
7	NULL
)	NULL
on	NULL
10°	NULL
Eu'*-labeled	NULL
syngeneic	NULL
target	NULL
cells	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
100	NULL
pl	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.5	NULL
uM	NULL
of	NULL
peptide	NULL
Ad5E1A734_243	NULL
(	NULL
14	NULL
)	NULL
,	NULL
peptide	NULL
AdS5E1B192-200	NULL
(	NULL
18	NULL
)	NULL
,	NULL
or	NULL
the	NULL
HPV16	NULL
E749	NULL
$	NULL
_-s7-encoded	NULL
peptide	NULL
Arg-Ala-His-Tyr-Asn-Ile-Val-Thr-Phe	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Microcultures	NULL
were	NULL
scored	NULL
as	NULL
responding	NULL
and	NULL
nonresponding	NULL
cultures	NULL
.	NULL

Responding	NULL
cultures	NULL
were	NULL
defined	NULL
as	NULL
those	NULL
in	NULL
which	NULL
the	NULL
Eu'+*	NULL
release	NULL
value	NULL
exceeded	NULL
the	NULL
mean	NULL
background	NULL
Eu®*	NULL
release	NULL
plus	NULL
three	NULL
times	NULL
the	NULL
standard	NULL
deviation	NULL
.	NULL

Limiting	NULL
dilution	NULL
analysis	NULL
predicts	NULL
that	NULL
if	NULL
37	NULL
%	NULL
of	NULL
the	NULL
tested	NULL
microcultures	NULL
is	NULL
negative	NULL
,	NULL
then	NULL
for	NULL
that	NULL
given	NULL
responder	NULL
cell	NULL
concentration	NULL
there	NULL
is	NULL
an	NULL
average	NULL
of	NULL
one	NULL
CTL-precursor	NULL
per	NULL
well	NULL
(	NULL
20	NULL
)	NULL
.	NULL

CTL-precursor	NULL
frequencies	NULL
were	NULL
only	NULL
taken	NULL
into	NULL
account	NULL
if	NULL
the	NULL
goodness	NULL
of	NULL
fit	NULL
was	NULL
=	NULL
<	NULL
12.5	NULL
(	NULL
jacknife	NULL
method	NULL
;	NULL
ref	NULL
.	NULL

21	NULL
)	NULL
.	NULL

In	NULL
Vivo	NULL
Administration	NULL
of	NULL
Tumor-Specific	NULL
CTL	NULL
Clones	NULL
.	NULL

In	NULL
vivo	NULL
therapy	NULL
for	NULL
AdSEl-induced	NULL
tumors	NULL
with	NULL
tumor-specific	NULL
CTL	NULL
clones	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
short	NULL
,	NULL
B6	NULL
nu/nu	NULL
mice	NULL
with	NULL
AdS5E1-induced	NULL
tumors	NULL
ranging	NULL
from	NULL
40-50	NULL
mm	NULL
?	NULL

were	NULL
treated	NULL
with	NULL
intravenous	NULL
injections	NULL
of	NULL
B6	NULL
Ad5SE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
(	NULL
1.5	NULL
%	NULL
10	NULL
``	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
10°	NULL
Cetus	NULL
Units	NULL
rIL-2	NULL
,	NULL
administered	NULL
s.c.	NULL
mixed	NULL
with	NULL
100	NULL
pg	NULL
of	NULL
peptide	NULL
AdS5E1A	NULL
;	NULL
34-243	NULL
or	NULL
100	NULL
ug	NULL
of	NULL
peptide	NULL
Ad5E1B192-200	NULL
as	NULL
a	NULL
control	NULL
in	NULL
IFA	NULL
containing	NULL
0.5	NULL
%	NULL
BSA	NULL
at	NULL
a	NULL
site	NULL
distant	NULL
from	NULL
the	NULL
tumor	NULL
.	NULL

The	NULL
mixtures	NULL
of	NULL
peptide/IL-2	NULL
and	NULL
IFA	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
RESULTS	NULL
Generation	NULL
of	NULL
AdS5E1A	NULL
+	NULL
ras	NULL
Transformed	NULL
Tumor	NULL
Cells	NULL
.	NULL

Previously	NULL
,	NULL
we	NULL
described	NULL
a	NULL
CTL	NULL
epitope	NULL
encoded	NULL
by	NULL
the	NULL
AdSE1A	NULL
region	NULL
(	NULL
AdSE1A	NULL
»	NULL
34-	NULL
»	NULL
y43	NULL
)	NULL
.	NULL

This	NULL
CTL	NULL
epitope	NULL
is	NULL
presented	NULL
to	NULL
the	NULL
immune	NULL
system	NULL
in	NULL
the	NULL
context	NULL
of	NULL
H-2D®	NULL
,	NULL
and	NULL
CTL	NULL
clones	NULL
directed	NULL
against	NULL
this	NULL
epitope	NULL
are	NULL
able	NULL
to	NULL
eradicate	NULL
large	NULL
established	NULL
AdSE1-induced	NULL
tumors	NULL
in	NULL
B6	NULL
nude	NULL
mice	NULL
(	NULL
14	NULL
,	NULL
22	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
the	NULL
AdSE1A-encoded	NULL
epitope	NULL
is	NULL
able	NULL
to	NULL
elicit	NULL
CTL	NULL
capable	NULL
of	NULL
mediating	NULL
tumor	NULL
regression	NULL
of	NULL
Ad5E1A-expressing	NULL
tumors	NULL
in	NULL
vivo	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
vaccination	NULL
with	NULL
this	NULL
CTL	NULL
epitope	NULL
is	NULL
also	NULL
able	NULL
to	NULL
induce	NULL
protective	NULL
immunity	NULL
against	NULL
AdSE1A-expressing	NULL
tumor	NULL
cells	NULL
in	NULL
immunocompetent	NULL
mice	NULL
,	NULL
we	NULL
generated	NULL
tumor	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
AdSE1A	NULL
region	NULL
and	NULL
an	NULL
activated	NULL
ras	NULL
oncogene	NULL
.	NULL

The	NULL
AdSEIA	NULL
+	NULL
ras	NULL
transformed	NULL
cells	NULL
are	NULL
recognized	NULL
by	NULL
Ad5E1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
,	NULL
showing	NULL
that	NULL
these	NULL
tumor	NULL
cells	NULL
present	NULL
the	NULL
AdS5E1Ap34-	NULL
»	NULL
s-encoded	NULL
CTL	NULL
epitope	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
AdSE1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
AdSE1-transformed	NULL
cells	NULL
,	NULL
are	NULL
tumorigenic	NULL
in	NULL
immunocompetent	NULL
mice	NULL
,	NULL
so	NULL
that	NULL
they	NULL
can	NULL
be	NULL
used	NULL
to	NULL
study	NULL
the	NULL
effects	NULL
of	NULL
vaccination	NULL
with	NULL
peptide	NULL
AdSE1Ap34.-	NULL
»	NULL
43	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
protective	NULL
CTL	NULL
mediated	NULL
immunity	NULL
against	NULL
tumor	NULL
outgrowth	NULL
in	NULL
vivo	NULL
.	NULL

A	NULL
dose	NULL
of	NULL
10	NULL
``	NULL
tumor	NULL
cells	NULL
injected	NULL
s.c.	NULL
causes	NULL
growth	NULL
of	NULL
small	NULL
tumors	NULL
in	NULL
80-100	NULL
%	NULL
of	NULL
the	NULL
mice	NULL
.	NULL

By	NULL
day	NULL
40	NULL
,	NULL
~10-30	NULL
%	NULL
of	NULL
the	NULL
animals	NULL
die	NULL
because	NULL
of	NULL
a	NULL
progressively	NULL
growing	NULL
tumor	NULL
.	NULL

The	NULL
other	NULL
animals	NULL
,	NULL
which	NULL
have	NULL
developed	NULL
a	NULL
tumor	NULL
,	NULL
still	NULL
carry	NULL
it	NULL
or	NULL
have	NULL
eradicated	NULL
the	NULL
tumor	NULL
(	NULL
5-10	NULL
%	NULL
of	NULL
the	NULL
animals	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
AdSE1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
are	NULL
weakly	NULL
immunogenic	NULL
in	NULL
immunocompetent	NULL
mice	NULL
.	NULL

Immunization	NULL
with	NULL
the	NULL
AdS5E1A-Encoded	NULL
CTL	NULL
Epitope	NULL
Leads	NULL
to	NULL
an	NULL
Enhanced	NULL
Outgrowth	NULL
of	NULL
AdSE1A	NULL
+	NULL
ras	NULL
Expressing	NULL
Tumor	NULL
Cells	NULL
,	NULL
Immunocompetent	NULL
B6	NULL
mice	NULL
were	NULL
immunized	NULL
once	NULL
s.c.	NULL
with	NULL
peptide	NULL
AdSE1Ap34-	NULL
»	NULL
43	NULL
in	NULL
IFA	NULL
,	NULL
a	NULL
vaccination	NULL
protocol	NULL
that	NULL
has	NULL
been	NULL
successfully	NULL
used	NULL
to	NULL
induce	NULL
protective	NULL
immunity	NULL
in	NULL
several	NULL
other	NULL
models	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Two	NULL
weeks	NULL
later	NULL
the	NULL
mice	NULL
were	NULL
challenged	NULL
with	NULL
AdS5E1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
.	NULL

Control	NULL
mice	NULL
immunized	NULL
with	NULL
irradiated	NULL
tumor	NULL
cells	NULL
were	NULL
protected	NULL
against	NULL
the	NULL
outgrowth	NULL
of	NULL
Ad5E1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
protective	NULL
immunity	NULL
can	NULL
be	NULL
established	NULL
against	NULL
these	NULL
tumor	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Unexpectedly	NULL
,	NULL
mice	NULL
immunized	NULL
with	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
were	NULL
not	NULL
protected	NULL
against	NULL
the	NULL
outgrowth	NULL
of	NULL
these	NULL
tumor	NULL
cells	NULL
.	NULL

Instead	NULL
,	NULL
the	NULL
tumors	NULL
in	NULL
these	NULL
animals	NULL
grew	NULL
faster	NULL
than	NULL
the	NULL
tumors	NULL
in	NULL
animals	NULL
that	NULL
were	NULL
injected	NULL
with	NULL
IFA	NULL
only	NULL
,	NULL
or	NULL
with	NULL
the	NULL
H-2D®-binding	NULL
control	NULL
peptide	NULL
HPV16	NULL
E749-5	NULL
;	NULL
in	NULL
IFA	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

All	NULL
animals	NULL
vaccinated	NULL
with	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
died	NULL
within	NULL
40	NULL
days	NULL
after	NULL
tumor	NULL
challenge	NULL
,	NULL
whereas	NULL
at	NULL
that	NULL
time	NULL
almost	NULL
all	NULL
animals	NULL
in	NULL
the	NULL
control	NULL
groups	NULL
were	NULL
still	NULL
alive	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
immunization	NULL
with	NULL
peptide	NULL
AdSE1Ap34-243	NULL
leads	NULL
to	NULL
the	NULL
inability	NULL
of	NULL
immunized	NULL
mice	NULL
to	NULL
control	NULL
the	NULL
outgrowth	NULL
of	NULL
AdSE1A-expressing	NULL
tumors	NULL
.	NULL

This	NULL
effect	NULL
is	NULL
induced	NULL
very	NULL
rap-idly	NULL
,	NULL
since	NULL
injection	NULL
of	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
at	NULL
the	NULL
left	NULL
flank	NULL
and	NULL
a	NULL
tumor	NULL
cell	NULL
challenge	NULL
on	NULL
the	NULL
right	NULL
flank	NULL
of	NULL
the	NULL
animal	NULL
on	NULL
the	NULL
same	NULL
day	NULL
resulted	NULL
in	NULL
the	NULL
enhancement	NULL
of	NULL
tumor	NULL
outgrowth	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

To	NULL
define	NULL
the	NULL
minimum	NULL
amount	NULL
of	NULL
peptide	NULL
required	NULL
to	NULL
observe	NULL
the	NULL
enhancement	NULL
of	NULL
tumor	NULL
outgrowth	NULL
,	NULL
we	NULL
titrated	NULL
the	NULL
injected	NULL
dose	NULL
of	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Mice	NULL
injected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
AdS5E1A	NULL
peptide	NULL
develop	NULL
rapidly	NULL
growing	NULL
tumors	NULL
earlier	NULL
and	NULL
died	NULL
sooner	NULL
than	NULL
animals	NULL
injected	NULL
with	NULL
lower	NULL
doses	NULL
of	NULL
peptide	NULL
or	NULL
an	NULL
H-2D®-binding	NULL
control	NULL
peptide	NULL
(	NULL
P	NULL
=	NULL
0.004	NULL
;	NULL
log-rank	NULL
test	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Protective	NULL
immunity	NULL
against	NULL
the	NULL
outgrowth	NULL
of	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
induced	NULL
at	NULL
any	NULL
concentration	NULL
of	NULL
peptide	NULL
(	NULL
ranging	NULL
from	NULL
10	NULL
pg	NULL
to	NULL
1	NULL
ng	NULL
peptide	NULL
per	NULL
mouse	NULL
)	NULL
,	NULL
since	NULL
the	NULL
tumor-take	NULL
in	NULL
mice	NULL
receiving	NULL
the	NULL
AdS5E1IA	NULL
peptide	NULL
was	NULL
the	NULL
same	NULL
as	NULL
the	NULL
tumor-take	NULL
in	NULL
mice	NULL
receiving	NULL
the	NULL
AdS5E1B	NULL
control	NULL
peptide	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Administration	NULL
of	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
,	NULL
and	NULL
not	NULL
of	NULL
other	NULL
peptides	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
leads	NULL
to	NULL
the	NULL
enhanced	NULL
outgrowth	NULL
of	NULL
Immunology	NULL
:	NULL
Toes	NULL
et	NULL
al	NULL
.	NULL

1800	NULL
100	NULL
&	NULL
HA	NULL
A	NULL
B	NULL
1500	NULL
=a	NULL
s	NULL
I®	NULL
-	NULL
&	NULL
g	NULL
1200	NULL
&	NULL
w	NULL
3	NULL
$	NULL
E	NULL
>	NULL
900	NULL
8	NULL
:	NULL
$	NULL
&	NULL
3	NULL
[	NULL
E	NULL
600	NULL
20	NULL
7	NULL
300	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
7857	NULL
§	NULL
f	NULL
€	NULL
Tumor	NULL
volume	NULL
(	NULL
mm	NULL
)	NULL
p	NULL
200	NULL
0	NULL
10	NULL
20	NULL
Days	NULL
-	NULL
30	NULL
10	NULL
20	NULL
30	NULL
40	NULL
Days	NULL
50	NULL
0	NULL
10	NULL
20	NULL
-	NULL
Days	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Vaccination	NULL
with	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
results	NULL
rapidly	NULL
in	NULL
the	NULL
inability	NULL
to	NULL
control	NULL
the	NULL
outgrowth	NULL
of	NULL
AdSE1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
s.c.	NULL
with	NULL
irradiated	NULL
Ad5E1A	NULL
+	NULL
ras	NULL
cells	NULL
in	NULL
PBS	NULL
(	NULL
0	NULL
)	NULL
,	NULL
left	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
,	NULL
immunized	NULL
with	NULL
50	NULL
ug	NULL
of	NULL
peptide	NULL
Ad5E1A234.-243	NULL
in	NULL
IFA	NULL
(	NULL
@	NULL
)	NULL
,	NULL
with	NULL
50	NULL
ug	NULL
control	NULL
peptide	NULL
HPV16	NULL
E749-57	NULL
in	NULL
IFA	NULL
(	NULL
0	NULL
)	NULL
,	NULL
or	NULL
with	NULL
IFA	NULL
only	NULL
(	NULL
a	NULL
)	NULL
.	NULL

Two	NULL
weeks	NULL
later	NULL
the	NULL
mice	NULL
were	NULL
challenged	NULL
with	NULL
live	NULL
Ad5E1A	NULL
+	NULL
ras	NULL
cells	NULL
on	NULL
the	NULL
other	NULL
flank	NULL
.	NULL

Tumors	NULL
in	NULL
mice	NULL
immunized	NULL
with	NULL
Ad5E1A	NULL
peptide	NULL
grow	NULL
more	NULL
rapidly	NULL
compared	NULL
with	NULL
tumors	NULL
in	NULL
animals	NULL
treated	NULL
with	NULL
control	NULL
peptide	NULL
(	NULL
P	NULL
<	NULL
0.0001	NULL
;	NULL
one-sided	NULL
Student	NULL
's	NULL
f	NULL
test	NULL
)	NULL
.	NULL

Mean	NULL
tumor	NULL
volumes	NULL
+	NULL
SEM	NULL
(	NULL
#	NULL
=	NULL
10	NULL
)	NULL
are	NULL
shown	NULL
in	NULL
mm*	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Mice	NULL
immunized	NULL
with	NULL
AdSE1A	NULL
peptide	NULL
die	NULL
sooner	NULL
because	NULL
of	NULL
a	NULL
progressively	NULL
growing	NULL
AdSE1A	NULL
+	NULL
ras	NULL
tumor	NULL
compared	NULL
with	NULL
mice	NULL
injected	NULL
with	NULL
control	NULL
peptide	NULL
(	NULL
P	NULL
=	NULL
0.0006	NULL
;	NULL
log-rank	NULL
test	NULL
)	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
enhanced	NULL
outgrowth	NULL
of	NULL
AdSE1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
is	NULL
induced	NULL
rapidly	NULL
after	NULL
peptide	NULL
vaccination	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
s.c.	NULL
on	NULL
day	NULL
zero	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
in	NULL
IFA	NULL
or	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
HPV16	NULL
E7-encoded	NULL
control	NULL
peptide	NULL
in	NULL
IFA	NULL
and	NULL
on	NULL
the	NULL
same	NULL
day	NULL
,	NULL
on	NULL
the	NULL
other	NULL
flank	NULL
,	NULL
injected	NULL
with	NULL
live	NULL
AdSE1A	NULL
+	NULL
ras	NULL
transformed	NULL
tumor	NULL
cells	NULL
.	NULL

Mice	NULL
receiving	NULL
AdSE1A	NULL
peptide	NULL
develop	NULL
bigger	NULL
tumors	NULL
than	NULL
mice	NULL
injected	NULL
with	NULL
control	NULL
peptide	NULL
.	NULL

Mean	NULL
tumor	NULL
volumes	NULL
+	NULL
SEM	NULL
(	NULL
#	NULL
=	NULL
5	NULL
)	NULL
are	NULL
shown	NULL
in	NULL
mm*	NULL
.	NULL

Ad5E1A-expressing	NULL
tumors	NULL
.	NULL

This	NULL
shows	NULL
that	NULL
these	NULL
tumors	NULL
do	NULL
not	NULL
grow	NULL
more	NULL
rapidly	NULL
when	NULL
control	NULL
peptides	NULL
are	NULL
injected	NULL
,	NULL
but	NULL
only	NULL
when	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
is	NULL
given	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
effect	NULL
is	NULL
peptide-specific	NULL
.	NULL

To	NULL
show	NULL
that	NULL
immunization	NULL
with	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
leads	NULL
to	NULL
the	NULL
enhanced	NULL
outgrowth	NULL
of	NULL
AdSEI1A-expressing	NULL
tumors	NULL
,	NULL
and	NULL
not	NULL
of	NULL
other	NULL
tumor	NULL
types	NULL
,	NULL
we	NULL
immunized	NULL
B6	NULL
mice	NULL
with	NULL
the	NULL
HPV16	NULL
E749-s7-derived	NULL
CTL	NULL
epitope	NULL
mixed	NULL
with	NULL
the	NULL
Ad5E1A	NULL
;	NULL
34-243	NULL
peptide	NULL
.	NULL

Mice	NULL
were	NULL
challenged	NULL
with	NULL
HPV16-transformed	NULL
tumor	NULL
cells	NULL
.	NULL

Immunization	NULL
with	NULL
peptide	NULL
HPV16	NULL
E74	NULL
$	NULL
-s7	NULL
;	NULL
induces	NULL
protective	NULL
CTL-mediated	NULL
immunity	NULL
against	NULL
HPV16-induced	NULL
tumors	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Mice	NULL
immunized	NULL
with	NULL
the	NULL
mixture	NULL
of	NULL
Ad5E1A	NULL
and	NULL
HPV16	NULL
E7	NULL
peptides	NULL
in	NULL
IFA	NULL
are	NULL
equally	NULL
well	NULL
protected	NULL
against	NULL
a	NULL
subsequent	NULL
challenge	NULL
of	NULL
HPV16-transformed	NULL
tumor	NULL
cells	NULL
as	NULL
mice	NULL
immunized	NULL
with	NULL
HPV16	NULL
E7	NULL
peptide	NULL
in	NULL
IFA	NULL
only	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
tumor	NULL
growth	NULL
rates	NULL
of	NULL
HPV16-transformed	NULL
tumor	NULL
cells	NULL
in	NULL
mice	NULL
immunized	NULL
with	NULL
only	NULL
AdSElAp34-	NULL
»	NULL
43	NULL
was	NULL
the	NULL
same	NULL
as	NULL
the	NULL
tumor	NULL
growth	NULL
rate	NULL
in	NULL
control	NULL
mice	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
injection	NULL
of	NULL
peptide	NULL
Ad5E1A	NULL
;	NULL
734_	NULL
»	NULL
43	NULL
does	NULL
not	NULL
result	NULL
in	NULL
a	NULL
general	NULL
inability	NULL
of	NULL
the	NULL
mice	NULL
to	NULL
reject	NULL
tumors	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
immunization	NULL
with	NULL
the	NULL
AdSE1A-encoded	NULL
CTL	NULL
epitope	NULL
leads	NULL
to	NULL
a	NULL
specific	NULL
functional	NULL
deletion	NULL
of	NULL
AdSE1A-specific	NULL
immunity	NULL
,	NULL
resulting	NULL
in	NULL
an	NULL
inability	NULL
to	NULL
reject	NULL
AdSE1A-expressing	NULL
tumors	NULL
.	NULL

Ad5E1A-Specific	NULL
Activity	NULL
Can	NULL
not	NULL
Be	NULL
Detected	NULL
After	NULL
Administration	NULL
of	NULL
the	NULL
AdS5E1A	NULL
Peptide	NULL
.	NULL

Immunization	NULL
with	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
leads	NULL
to	NULL
an	NULL
enhanced	NULL
outgrowth	NULL
of	NULL
Ad5E1A-expressing	NULL
tumors	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
AdSE1A-specific	NULL
CTL	NULL
190	NULL
``	NULL
be	NULL
I	NULL
heiliithal	NULL
I	NULL
lei	NULL
O	NULL
-O-	NULL
AdSEI1A	NULL
+	NULL
ras	NULL
J	NULL
``	NULL
-A-	NULL
-	NULL
50	NULL
pug	NULL
AdSE1A-peptide	NULL
so	NULL
1	NULL
T	NULL
&	NULL
-	NULL
@	NULL
-	NULL
-	NULL
10	NULL
ug	NULL
AdSELA-peptide	NULL
R	NULL
5	NULL
A	NULL
--	NULL
-6	NULL
2	NULL
60	NULL
-~	NULL
1	NULL
ug	NULL
AdSE1A-peptlde	NULL
F	NULL
-=-	NULL
-	NULL
0.1	NULL
ug	NULL
AdSE1A-peptide	NULL
8	NULL
aJ	NULL
p	NULL
5	NULL
40	NULL
A	NULL
-	NULL
&	NULL
-	NULL
-	NULL
0.01	NULL
ug	NULL
AdSE1A-peptide	NULL
201	NULL
-O-	NULL
-	NULL
0.001	NULL
pg	NULL
AdSE1A-peptide	NULL
&	NULL
--	NULL
-e	NULL
-+-	NULL
-	NULL
10	NULL
pug	NULL
AdSE1B-peptide	NULL
0	NULL
v	NULL
r	NULL
ba	NULL
J	NULL
10	NULL
20	NULL
30	NULL
40	NULL
-	NULL
Days	NULL
50	NULL
FiG	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Tumor	NULL
growth	NULL
of	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
after	NULL
titration	NULL
of	NULL
the	NULL
Ad5E1A234-243	NULL
peptide	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
s.c.	NULL
with	NULL
irradiated	NULL
AdS5E1A	NULL
+	NULL
ras	NULL
cells	NULL
,	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
Ad5E1B	NULL
;	NULL
192-2m-encoded	NULL
control	NULL
peptide	NULL
(	NULL
18	NULL
)	NULL
in	NULL
IFA	NULL
,	NULL
or	NULL
with	NULL
50	NULL
to	NULL
0.001	NULL
ug	NULL
of	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
in	NULL
IFA	NULL
.	NULL

Two	NULL
weeks	NULL
later	NULL
mice	NULL
were	NULL
challenged	NULL
with	NULL
live	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
on	NULL
the	NULL
other	NULL
flank	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
percentage	NULL
of	NULL
surviving	NULL
animals	NULL
.	NULL

are	NULL
tolerized	NULL
by	NULL
administration	NULL
of	NULL
the	NULL
Ad5SE1A-encoded	NULL
CTL	NULL
epitope	NULL
.	NULL

To	NULL
study	NULL
the	NULL
effect	NULL
of	NULL
administration	NULL
of	NULL
the	NULL
Ad5SE1A	NULL
peptide	NULL
on	NULL
AdSE1A-specific	NULL
CTL	NULL
activity	NULL
,	NULL
AdSE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
was	NULL
adoptively	NULL
transferred	NULL
into	NULL
naive	NULL
immung-competent	NULL
animals	NULL
.	NULL

Three	NULL
days	NULL
later	NULL
peptide	NULL
or	NULL
an	NULL
AdS5E1B	NULL
;	NULL
s2-200-encoded	NULL
control	NULL
peptide	NULL
(	NULL
17	NULL
)	NULL
were	NULL
ad-ministered	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
CTL	NULL
clone	NULL
5	NULL
in	NULL
the	NULL
spleen	NULL
of	NULL
these	NULL
animals	NULL
was	NULL
functionally	NULL
tested	NULL
6	NULL
days	NULL
later	NULL
.	NULL

CTL	NULL
clone	NULL
5	NULL
could	NULL
only	NULL
be	NULL
recovered	NULL
from	NULL
animals	NULL
that	NULL
received	NULL
CTL	NULL
clone	NULL
5	NULL
and	NULL
the	NULL
AdSE1B	NULL
control	NULL
peptide	NULL
,	NULL
but	NULL
not	NULL
from	NULL
animals	NULL
that	NULL
received	NULL
CTL	NULL
clone	NULL
5	NULL
and	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Administration	NULL
of	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
adoptively	NULL
transferred	NULL
AdSE1B-specific	NULL
CTL	NULL
clones	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
study	NULL
whether	NULL
the	NULL
AdSEI1A	NULL
peptide	NULL
had	NULL
also	NULL
an	NULL
effect	NULL
on	NULL
naive	NULL
AdS5E1A-specific	NULL
CTL	NULL
,	NULL
B6	NULL
mice	NULL
expressing	NULL
a	NULL
transgenic	NULL
TCR	NULL
specific	NULL
for	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
were	NULL
injected	NULL
with	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
splenocytes	NULL
from	NULL
normal	NULL
B6	NULL
mice	NULL
,	NULL
splenocytes	NULL
from	NULL
naive	NULL
TCR-transgenic	NULL
mice	NULL
,	NULL
when	NULL
restimulated	NULL
in	NULL
vitro	NULL
with	NULL
Ad5E1A	NULL
peptide-loaded	NULL
lipopolysaccharide	NULL
blasts	NULL
,	NULL
display	NULL
strong	NULL
cyto-lytic	NULL
activity	NULL
against	NULL
Ad5E1-transformed	NULL
cells	NULL
.	NULL

After	NULL
injection	NULL
of	NULL
the	NULL
AdS5E1A	NULL
peptide	NULL
,	NULL
but	NULL
not	NULL
of	NULL
an	NULL
irrelevant	NULL
control	NULL
peptide	NULL
,	NULL
the	NULL
spleen	NULL
cell	NULL
cultures	NULL
derived	NULL
from	NULL
Ad5SE1	NULL
A-specific	NULL
TCR-transgenic	NULL
animals	NULL
are	NULL
no	NULL
longer	NULL
able	NULL
to	NULL
lyse	NULL
Ad5E1-transformed	NULL
tumor	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
com	NULL
4	NULL
®	NULL
g	NULL
IFA	NULL
E	NULL
E	NULL
T	NULL
H	NULL
HPV16	NULL
E7-peptide	NULL
&	NULL
so|	NULL
||	NULL
D	NULL
HPV16	NULL
E7-peptide	NULL
+	NULL
so	NULL
AdSE1A-peptide	NULL
&	NULL
$	NULL
m	NULL
40	NULL
F	NULL
0	NULL
E	NULL
E	NULL
20	NULL
S	NULL
24	NULL
Days	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
immunization	NULL
with	NULL
the	NULL
Ad5E1A	NULL
;	NULL
34_243	NULL
peptide	NULL
is	NULL
tumor-specific	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
HPV16	NULL
E745_s7	NULL
peptide	NULL
in	NULL
IFA	NULL
,	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
10	NULL
ug	NULL
HPV16	NULL
E7	NULL
peptide	NULL
and	NULL
10	NULL
ug	NULL
AdSE1A	NULL
peptide	NULL
in	NULL
IFA	NULL
or	NULL
with	NULL
IFA	NULL
only	NULL
.	NULL

Two	NULL
weeks	NULL
later	NULL
mice	NULL
were	NULL
challenged	NULL
with	NULL
HPV16-transformed	NULL
tumor	NULL
cells	NULL
.	NULL

The	NULL
HPV16	NULL
E749-57	NULL
peptide	NULL
induces	NULL
protective	NULL
immunity	NULL
against	NULL
a	NULL
challenge	NULL
with	NULL
HPV16	NULL
E7-transformed	NULL
tumor	NULL
cells	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Mice	NULL
immunized	NULL
with	NULL
the	NULL
peptide	NULL
mixture	NULL
are	NULL
also	NULL
protected	NULL
(	NULL
P	NULL
=	NULL
0.03	NULL
,	NULL
log-rank	NULL
test	NULL
)	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
percentage	NULL
of	NULL
tumor-bearing	NULL
mice	NULL
on	NULL
several	NULL
days	NULL
after	NULL
tumor	NULL
challenge	NULL
.	NULL

7858	NULL
Immunology	NULL
:	NULL
Toes	NULL
et	NULL
al	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Adoptively	NULL
transferred	NULL
Ad5SE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
is	NULL
functionally	NULL
deleted	NULL
by	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
in	NULL
vivo	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Table	NULL
2	NULL
.	NULL

Combination	NULL
therapy	NULL
with	NULL
adoptively	NULL
transferred	NULL
CTL	NULL
clone	NULL
5	NULL
and	NULL
AdSE1A	NULL
peptide	NULL
leads	NULL
to	NULL
the	NULL
death	NULL
of	NULL
mice	NULL
.	NULL

RMA	NULL
+	NULL
RMA	NULL
+	NULL
RMA	NULL
+	NULL
E749-s7	NULL
E1B192-200	NULL
E1Ar34-243	NULL
Exp	NULL
.	NULL

1	NULL
Clone	NULL
5	NULL
+	NULL
E1B192-200	NULL
1	NULL
+1	NULL
2	NULL
+	NULL
1	NULL
80	NULL
+	NULL
10	NULL
Clone	NULL
5	NULL
+	NULL
E1Az34-243	NULL
2	NULL
+	NULL
4	NULL
+	NULL
2	NULL
4	NULL
+	NULL
2	NULL
Exp	NULL
.	NULL

2	NULL
Clone	NULL
5	NULL
+	NULL
E1B192-200	NULL
2	NULL
*	NULL
1	NULL
8	NULL
£	NULL
1	NULL
174	NULL
+	NULL
21	NULL
Clone	NULL
5	NULL
+	NULL
14	NULL
+	NULL
2	NULL
17	NULL
*	NULL
2	NULL
13	NULL
#	NULL
2	NULL
Ad5E1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
(	NULL
1.5	NULL
x	NULL
10	NULL
``	NULL
)	NULL
was	NULL
adoptively	NULL
transferred	NULL
by	NULL
intravenous	NULL
injection	NULL
to	NULL
naive	NULL
immuno-competent	NULL
B6	NULL
mice	NULL
at	NULL
day	NULL
0	NULL
.	NULL

At	NULL
day	NULL
3	NULL
these	NULL
animals	NULL
received	NULL
s.c.	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
or	NULL
the	NULL
Ad5E1B	NULL
peptide	NULL
in	NULL
IFA	NULL
.	NULL

At	NULL
day	NULL
9	NULL
the	NULL
spleen	NULL
cells	NULL
were	NULL
taken	NULL
and	NULL
put	NULL
in	NULL
limiting	NULL
dilution	NULL
.	NULL

At	NULL
day	NULL
16	NULL
the	NULL
contents	NULL
of	NULL
the	NULL
wells	NULL
were	NULL
tested	NULL
on	NULL
syngeneic	NULL
RMA	NULL
cells	NULL
loaded	NULL
with	NULL
0.5	NULL
uM	NULL
of	NULL
the	NULL
HPV16	NULL
E749-s7-encoded	NULL
control	NULL
peptide	NULL
,	NULL
the	NULL
Ad5E1B192-20p-encoded	NULL
control	NULL
peptide	NULL
,	NULL
or	NULL
the	NULL
Ad5E1A	NULL
;	NULL
34-	NULL
»	NULL
4s-encoded	NULL
peptide	NULL
.	NULL

Values	NULL
in	NULL
table	NULL
show	NULL
minimum	NULL
estimates	NULL
of	NULL
CTL	NULL
*+	NULL
SD	NULL
per	NULL
10°	NULL
spleen	NULL
cells	NULL
.	NULL

bined	NULL
data	NULL
on	NULL
tumor	NULL
outgrowth	NULL
and	NULL
AdSE1A-specific	NULL
CTL	NULL
activity	NULL
after	NULL
peptide	NULL
immunization	NULL
indicate	NULL
that	NULL
both	NULL
naive	NULL
and	NULL
preactivated	NULL
AdSE1A-specific	NULL
CTL	NULL
are	NULL
functionally	NULL
deleted	NULL
by	NULL
administration	NULL
of	NULL
the	NULL
AdSE1Ap34-	NULL
»	NULL
4s-encoded	NULL
CTL	NULL
epitope	NULL
.	NULL

The	NULL
AdS5E1A	NULL
Peptide	NULL
Rapidly	NULL
Diffuses	NULL
Through	NULL
the	NULL
Body	NULL
After	NULL
s.c.	NULL
Administration	NULL
in	NULL
IFA	NULL
.	NULL

The	NULL
data	NULL
described	NULL
above	NULL
indicate	NULL
that	NULL
intravenously	NULL
injected	NULL
AdSE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
is	NULL
functionally	NULL
deleted	NULL
in	NULL
vivo	NULL
by	NULL
s.c.	NULL
administration	NULL
of	NULL
the	NULL
AdSE1A-encoded	NULL
CTL	NULL
epitope	NULL
.	NULL

CTL	NULL
clone	NULL
5	NULL
is	NULL
able	NULL
to	NULL
eradicate	NULL
established	NULL
AdS5E1-induced	NULL
tumor	NULL
in	NULL
nude	NULL
mice	NULL
(	NULL
14	NULL
)	NULL
.	NULL

To	NULL
test	NULL
if	NULL
administration	NULL
of	NULL
the	NULL
AdSE1A-peptide	NULL
leads	NULL
to	NULL
the	NULL
inability	NULL
of	NULL
CTL	NULL
clone	NULL
5	NULL
to	NULL
eradicate	NULL
established	NULL
AdSE1-induced	NULL
tumors	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
treated	NULL
Ad5SE1	NULL
tumor-bearing	NULL
nude	NULL
mice	NULL
by	NULL
intravenous	NULL
injection	NULL
of	NULL
CTL	NULL
clone	NULL
5	NULL
.	NULL

At	NULL
the	NULL
same	NULL
time	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
,	NULL
or	NULL
as	NULL
a	NULL
control	NULL
,	NULL
the	NULL
AdSE1B192-200-encoded	NULL
peptide	NULL
,	NULL
was	NULL
given	NULL
s.c.	NULL
together	NULL
with	NULL
rIL-2	NULL
in	NULL
IFA	NULL
.	NULL

Unexpectedly	NULL
,	NULL
the	NULL
animals	NULL
that	NULL
received	NULL
CTL	NULL
clone	NULL
5	NULL
and	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
died	NULL
within	NULL
16	NULL
h	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
,	NULL
whereas	NULL
animals	NULL
that	NULL
received	NULL
only	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
or	NULL
CTL	NULL
clone	NULL
5	NULL
together	NULL
with	NULL
the	NULL
AdSE1B	NULL
peptide	NULL
survived	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

Mice	NULL
that	NULL
received	NULL
an	NULL
AdSE1B-specific	NULL
CTL	NULL
clone	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
survived	NULL
and	NULL
eradicated	NULL
the	NULL
AdSE1-induced	NULL
tumors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
findings	NULL
were	NULL
obtained	NULL
in	NULL
immunocompetent	NULL
animals	NULL
that	NULL
received	NULL
CTL	NULL
clone	NULL
5	NULL
at	NULL
the	NULL
same	NULL
time	NULL
as	NULL
the	NULL
Ad5E1A	NULL
peptide	NULL
,	NULL
together	NULL
with	NULL
rIL-2	NULL
.	NULL

Autopsy	NULL
revealed	NULL
that	NULL
animals	NULL
receiving	NULL
the	NULL
combination	NULL
of	NULL
60	NULL
4	NULL
£	NULL
``	NULL
~	NULL
40	NULL
2	NULL
B	NULL
9	NULL
A	NULL
w	NULL
*~	NULL
Bf	NULL
9	NULL
u	NULL
r	NULL
1	NULL
0	NULL
5	NULL
10	NULL
15	NULL
E/T	NULL
20	NULL
FiG	NULL
.	NULL

4	NULL
.	NULL

Injection	NULL
of	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
deletes	NULL
naive	NULL
Ad5SEI1A-specific	NULL
CTL	NULL
activity	NULL
.	NULL

Naive	NULL
B6	NULL
mice	NULL
,	NULL
expressing	NULL
a	NULL
transgenic	NULL
TCR	NULL
specific	NULL
for	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
,	NULL
were	NULL
injected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
AdS5E1A734-243	NULL
peptide	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
or	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
HPV16	NULL
E749-s7	NULL
peptide	NULL
(	NULL
solid	NULL
symbols	NULL
)	NULL
s.c.	NULL
in	NULL
IFA	NULL
.	NULL

Six	NULL
days	NULL
later	NULL
5	NULL
x	NULL
10°	NULL
spleen	NULL
cells	NULL
of	NULL
these	NULL
animals	NULL
were	NULL
restimulated	NULL
with	NULL
25	NULL
%	NULL
AdSE1A	NULL
peptide-loaded	NULL
lipopolysaccharide	NULL
blasts	NULL
in	NULL
a	NULL
24-well	NULL
plate	NULL
.	NULL

After	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
the	NULL
bulk	NULL
CTL	NULL
cultures	NULL
were	NULL
tested	NULL
on	NULL
untransformed	NULL
B6	NULL
MEC	NULL
(	NULL
@	NULL
,	NULL
O0	NULL
)	NULL
or	NULL
AdSE1-transformed	NULL
tumor	NULL
cells	NULL
(	NULL
@	NULL
,	NULL
C	NULL
)	NULL
.	NULL

Shown	NULL
is	NULL
the	NULL
percentage	NULL
of	NULL
specific	NULL
lysis	NULL
at	NULL
different	NULL
effector-to-target	NULL
cell	NULL
ratios	NULL
.	NULL

Treatment	NULL
AdSE1A734-243	NULL
,	NULL
%	NULL
Ad5E1B192-200	NULL
,	NULL
%	NULL
_-	NULL
0	NULL
0	NULL
CTL	NULL
clone	NULL
5	NULL
,	NULL
iv	NULL
.	NULL

100	NULL
0	NULL
AdS5E1-tumor-bearing	NULL
nude	NULL
mice	NULL
(	NULL
5	NULL
animals	NULL
per	NULL
group	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
AdSE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
by	NULL
intravenous	NULL
(	NULL
iv	NULL
.	NULL
)	NULL

injection	NULL
.	NULL

At	NULL
the	NULL
same	NULL
day	NULL
these	NULL
mice	NULL
received	NULL
10°	NULL
Cetus	NULL
units	NULL
rIL-2	NULL
mixed	NULL
with	NULL
100	NULL
ug	NULL
peptide	NULL
in	NULL
IFA	NULL
.	NULL

Sixteen	NULL
hours	NULL
later	NULL
all	NULL
animals	NULL
receiving	NULL
AdSE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
and	NULL
AdSE1A	NULL
peptide	NULL
were	NULL
dead	NULL
.	NULL

In	NULL
all	NULL
animals	NULL
receiving	NULL
CTL	NULL
clone	NULL
5	NULL
and	NULL
the	NULL
AdSE1B-encoded	NULL
control	NULL
peptide	NULL
,	NULL
tumors	NULL
were	NULL
eradicated	NULL
.	NULL

Values	NULL
in	NULL
table	NULL
show	NULL
percentage	NULL
of	NULL
dead	NULL
mice	NULL
.	NULL

CTL	NULL
clone	NULL
5	NULL
and	NULL
AdSE1A	NULL
peptide	NULL
had	NULL
severely	NULL
congested	NULL
lungs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Apparently	NULL
,	NULL
the	NULL
adoptively	NULL
transferred	NULL
AdSE1A-specific	NULL
CTL	NULL
that	NULL
are	NULL
trapped	NULL
in	NULL
the	NULL
capillary	NULL
bed	NULL
of	NULL
the	NULL
lungs	NULL
become	NULL
activated	NULL
by	NULL
injection	NULL
of	NULL
the	NULL
AdSEI1A	NULL
peptide	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
observed	NULL
lung	NULL
pathology	NULL
.	NULL

The	NULL
mechanisms	NULL
involved	NULL
in	NULL
induction	NULL
of	NULL
this	NULL
lung	NULL
pathology	NULL
falls	NULL
beyond	NULL
the	NULL
scope	NULL
of	NULL
this	NULL
study	NULL
and	NULL
are	NULL
now	NULL
under	NULL
further	NULL
investigation	NULL
.	NULL

Nonetheless	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
s.c.	NULL
administrated	NULL
AdSE1A	NULL
;	NULL
34-243	NULL
peptide	NULL
in	NULL
IFA	NULL
rapidly	NULL
diffuses	NULL
throughout	NULL
the	NULL
body	NULL
where	NULL
it	NULL
is	NULL
recognized	NULL
by	NULL
AdSE1A-specific	NULL
CTL	NULL
.	NULL

Protective	NULL
Immunity	NULL
Induced	NULL
by	NULL
Vaccination	NULL
with	NULL
Adeno-virus	NULL
.	NULL

Immunization	NULL
with	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
leads	NULL
to	NULL
AdSE1A-specific	NULL
CTL	NULL
tolerance	NULL
and	NULL
severely	NULL
affects	NULL
the	NULL
ability	NULL
of	NULL
B6	NULL
mice	NULL
to	NULL
cope	NULL
with	NULL
AdSE1A-expressing	NULL
tumors	NULL
.	NULL

Immunization	NULL
with	NULL
irradiated	NULL
tumor	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
induces	NULL
protective	NULL
immunity	NULL
against	NULL
these	NULL
tumor	NULL
cells	NULL
,	NULL
showing	NULL
the	NULL
feasibility	NULL
to	NULL
induce	NULL
protective	NULL
immunity	NULL
against	NULL
Ad5E1A	NULL
+	NULL
ras	NULL
transformed	NULL
cells	NULL
.	NULL

Vaccination	NULL
with	NULL
irradiated	NULL
tumor	NULL
cells	NULL
will	NULL
,	NULL
however	NULL
,	NULL
be	NULL
difficult	NULL
to	NULL
execute	NULL
on	NULL
a	NULL
large	NULL
scale	NULL
in	NULL
a	NULL
clinical	NULL
setting	NULL
.	NULL

Recombinant	NULL
adenoviruses	NULL
might	NULL
serve	NULL
as	NULL
efficient	NULL
vaccine	NULL
vehicles	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
protective	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

Recombinant	NULL
adenoviruses	NULL
are	NULL
currently	NULL
being	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
deliver	NULL
genes	NULL
to	NULL
a	NULL
spectrum	NULL
of	NULL
nondividing	NULL
cells	NULL
in	NULL
vivo	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
genetic	NULL
diseases	NULL
.	NULL

The	NULL
use	NULL
of	NULL
recombinant	NULL
adenoviruses	NULL
is	NULL
associated	NULL
with	NULL
transient	NULL
gene	NULL
expression	NULL
due	NULL
to	NULL
a	NULL
T-cell-mediated	NULL
immune	NULL
response	NULL
against	NULL
vector-derived	NULL
proteins	NULL
(	NULL
23-25	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
recombinant	NULL
adenoviruses	NULL
might	NULL
also	NULL
be	NULL
used	NULL
to	NULL
induce	NULL
protective	NULL
immunity	NULL
against	NULL
tumors	NULL
,	NULL
when	NULL
they	NULL
contain	NULL
DNA	NULL
encoding	NULL
for	NULL
tumor	NULL
antigens	NULL
or	NULL
tumor-derived	NULL
T-cell	NULL
epitopes	NULL
.	NULL

To	NULL
test	NULL
if	NULL
adenoviruses	NULL
can	NULL
indeed	NULL
be	NULL
used	NULL
to	NULL
establish	NULL
protective	NULL
immunity	NULL
against	NULL
tumors	NULL
,	NULL
we	NULL
immunized	NULL
B6	NULL
mice	NULL
with	NULL
an	NULL
adenovirus	NULL
type	NULL
5	NULL
variant	NULL
(	NULL
¢s149	NULL
)	NULL
.	NULL

AdSts149	NULL
is	NULL
largely	NULL
replication	NULL
deficient	NULL
,	NULL
but	NULL
expresses	NULL
,	NULL
upon	NULL
infection	NULL
,	NULL
AdS5E1A-encoded	NULL
protein	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Mice	NULL
immunized	NULL
with	NULL
Ad5ts149	NULL
showed	NULL
high	NULL
CTL	NULL
reactivity	NULL
against	NULL
the	NULL
AdSE1lA-encoded	NULL
CTL	NULL
epitope	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
4	NULL
and	NULL
B	NULL
)	NULL
and	NULL
are	NULL
protected	NULL
against	NULL
a	NULL
subsequent	NULL
challenge	NULL
with	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
show	NULL
the	NULL
possibility	NULL
to	NULL
use	NULL
recombinant	NULL
adenoviruses	NULL
expressing	NULL
tumor	NULL
antigens	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
tumor-specific	NULL
protective	NULL
immunity	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
report	NULL
we	NULL
show	NULL
that	NULL
a	NULL
single	NULL
s.c.	NULL
immunizaton	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
Ad5E1Ap34_	NULL
»	NULL
4s-encoded	NULL
CTL	NULL
epitope	NULL
rather	NULL
than	NULL
inducing	NULL
protective	NULL
immunity	NULL
against	NULL
a	NULL
challenge	NULL
of	NULL
AdSE1A-expressing	NULL
tumor	NULL
cells	NULL
instead	NULL
causes	NULL
faster	NULL
tumor	NULL
outgrowth	NULL
.	NULL

This	NULL
effect	NULL
is	NULL
peptide-specific	NULL
and	NULL
is	NULL
rapidly	NULL
in-duced	NULL
.	NULL

AdSE1A-specific	NULL
CTL	NULL
activity	NULL
can	NULL
no	NULL
longer	NULL
be	NULL
detected	NULL
after	NULL
injection	NULL
of	NULL
the	NULL
Ad5SE1A	NULL
peptide	NULL
from	NULL
animals	NULL
that	NULL
express	NULL
an	NULL
AdSE1A-specific	NULL
transgenic	NULL
TCR	NULL
or	NULL
that	NULL
have	NULL
received	NULL
Ad5SE1A-specific	NULL
CTL	NULL
clone	NULL
5	NULL
by	NULL
adoptive	NULL
transfer	NULL
.	NULL

Although	NULL
the	NULL
latter	NULL
observation	NULL
might	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
an	NULL
altered	NULL
migratory	NULL
pattern	NULL
of	NULL
the	NULL
Ad5E1A-specific	NULL
CTL	NULL
clone	NULL
,	NULL
Immunology	NULL
:	NULL
Toes	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
7859	NULL
1007	NULL
a	NULL
1097	NULL
]	NULL
p	NULL
1291	NULL
¢	NULL
m	NULL
#	NULL
m	NULL
~	NULL
C0	NULL
**A	NULL
so	NULL
ag	NULL
1000	NULL
3	NULL
-	NULL
@	NULL
-	NULL
_	NULL
RMA	NULL
+	NULL
AdSE1A-peptide	NULL
&	NULL
&	NULL
-D-	NULL
_	NULL
RMA	NULL
+	NULL
AdSE1B-peptide	NULL
o	NULL
s	NULL
-O-	NULL
AdSts149	NULL
+	NULL
pe	NULL
-O-	NULL
RMA	NULL
o	NULL
J	NULL
``	NULL
|	NULL
-=-	NULL
+m	NULL
®	NULL
5	NULL
PBs	NULL
g.	NULL
-	NULL
@	NULL
~	NULL
-	NULL
RMA	NULL
+	NULL
AdSE1A-peptide	NULL
2	NULL
-	NULL
s	NULL
-o-w	NULL
«	NULL
o	NULL
RMA	NULL
+	NULL
AdSE1B-peptide	NULL
E	NULL
-®-	NULL
-	NULL
AdSEIA	NULL
+	NULL
ras	NULL
cells	NULL
5	NULL
ao	NULL
E	NULL
200	NULL
0	NULL
15	NULL
30	NULL
45	NULL
ET	NULL
60	NULL
0	NULL
15	NULL
30	NULL
45	NULL
ET	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
Days	NULL
40	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Vaccination	NULL
with	NULL
a	NULL
mutant	NULL
adenovirus	NULL
type	NULL
5	NULL
,	NULL
expressing	NULL
Ad5E1A	NULL
,	NULL
induces	NULL
AdSE1A-specific	NULL
CTL	NULL
activity	NULL
and	NULL
protects	NULL
against	NULL
a	NULL
subsequent	NULL
challenge	NULL
with	NULL
AdS5E1A	NULL
+	NULL
ras	NULL
cells	NULL
.	NULL

B6	NULL
mice	NULL
were	NULL
immunized	NULL
(	NULL
i.p	NULL
.	NULL
)	NULL

with	NULL
PBS	NULL
+	NULL
0.5	NULL
%	NULL
BSA	NULL
(	NULL
4	NULL
and	NULL
C	NULL
)	NULL
or	NULL
2	NULL
X	NULL
10°	NULL
plaque	NULL
forming	NULL
units	NULL
of	NULL
Ad5ts149	NULL
in	NULL
PBS	NULL
+	NULL
0.5	NULL
%	NULL
BSA	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Two	NULL
weeks	NULL
after	NULL
immunization	NULL
,	NULL
the	NULL
spleen	NULL
cells	NULL
of	NULL
these	NULL
mice	NULL
were	NULL
restimulated	NULL
in	NULL
vitro	NULL
with	NULL
10	NULL
%	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
(	NULL
4	NULL
and	NULL
B	NULL
)	NULL
,	NULL
or	NULL
the	NULL
mice	NULL
were	NULL
challenged	NULL
(	NULL
s.c.	NULL
)	NULL
with	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
lytic	NULL
activity	NULL
of	NULL
bulk	NULL
CTL	NULL
were	NULL
tested	NULL
after	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
against	NULL
AdSE1A	NULL
+	NULL
ras	NULL
cells	NULL
,	NULL
or	NULL
syngeneic	NULL
RMA	NULL
cells	NULL
loaded	NULL
with	NULL
0.5	NULL
uM	NULL
of	NULL
the	NULL
Ad5E1B192-20-encoded	NULL
control	NULL
peptide	NULL
or	NULL
the	NULL
peptide	NULL
Shown	NULL
are	NULL
the	NULL
percentages	NULL
of	NULL
specific	NULL
ly31s	NULL
at	NULL
different	NULL
effector-to-target	NULL
cell	NULL
ratios	NULL
(	NULL
4	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
tumor	NULL
volumes	NULL
+	NULL
SEM	NULL
(	NULL
n	NULL
=	NULL
7	NULL
)	NULL
of	NULL
mice	NULL
challenged	NULL
with	NULL
tumor	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
mm*	NULL
in	NULL
C.	NULL
a	NULL
more	NULL
likely	NULL
explanation	NULL
is	NULL
functional	NULL
deletion	NULL
of	NULL
AdSE1A-specific	NULL
CTL	NULL
.	NULL

The	NULL
Ad5E1A	NULL
peptide	NULL
rapidly	NULL
diffuses	NULL
throughout	NULL
the	NULL
body	NULL
after	NULL
s.c.	NULL
injection	NULL
in	NULL
IFA	NULL
and	NULL
enhanced	NULL
tumor	NULL
outgrowth	NULL
is	NULL
also	NULL
observed	NULL
when	NULL
the	NULL
tumor	NULL
challenge	NULL
is	NULL
given	NULL
near	NULL
the	NULL
peptide-IFA	NULL
depot	NULL
in	NULL
the	NULL
same	NULL
lymph	NULL
nodes	NULL
draining	NULL
area	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
AdSE1A-specific	NULL
CTL	NULL
are	NULL
not	NULL
massively	NULL
attracted	NULL
to	NULL
the	NULL
peptide-IFA	NULL
depot	NULL
.	NULL

Unlike	NULL
mice	NULL
immunized	NULL
with	NULL
adeno-derived	NULL
peptides	NULL
,	NULL
mice	NULL
immunized	NULL
with	NULL
live	NULL
adenovirus	NULL
or	NULL
with	NULL
irradiated	NULL
tumor	NULL
cells	NULL
are	NULL
protected	NULL
against	NULL
a	NULL
subsequent	NULL
challenge	NULL
with	NULL
AdSE1A-expressing	NULL
tumor	NULL
cells	NULL
.	NULL

Great	NULL
effort	NULL
is	NULL
currently	NULL
directed	NULL
toward	NULL
the	NULL
development	NULL
of	NULL
successful	NULL
human	NULL
gene	NULL
therapies	NULL
employing	NULL
recombinant	NULL
adenoviruses	NULL
for	NULL
gene	NULL
transfer	NULL
.	NULL

One	NULL
obstacle	NULL
in	NULL
obtaining	NULL
stable	NULL
expression	NULL
of	NULL
the	NULL
delivered	NULL
gene	NULL
in	NULL
the	NULL
target	NULL
cells	NULL
using	NULL
this	NULL
method	NULL
is	NULL
a	NULL
vector	NULL
directed	NULL
,	NULL
T-cell-mediated	NULL
immune	NULL
response	NULL
(	NULL
23-25	NULL
)	NULL
.	NULL

By	NULL
introducing	NULL
tumor	NULL
antigens	NULL
or	NULL
(	NULL
several	NULL
)	NULL
tumor-encoded	NULL
T-cell	NULL
epitopes	NULL
in	NULL
these	NULL
adenovectors	NULL
it	NULL
is	NULL
possible	NULL
to	NULL
induce	NULL
protective	NULL
T-cell-mediated	NULL
anti-tumor	NULL
immunity	NULL
as	NULL
demonstrated	NULL
here	NULL
for	NULL
the	NULL
AdSE1A	NULL
epitope	NULL
.	NULL

Peptide-based	NULL
vaccination	NULL
has	NULL
been	NULL
proven	NULL
to	NULL
induce	NULL
T-cell-mediated	NULL
protective	NULL
immunity	NULL
in	NULL
several	NULL
viral	NULL
and	NULL
tumor	NULL
model	NULL
systems	NULL
(	NULL
5-7	NULL
,	NULL
9	NULL
,	NULL
27	NULL
)	NULL
.	NULL

At	NULL
the	NULL
same	NULL
time	NULL
peptides	NULL
have	NULL
been	NULL
found	NULL
capable	NULL
of	NULL
T-cell	NULL
tolerance	NULL
induction	NULL
(	NULL
12	NULL
,	NULL
13	NULL
,	NULL
28-31	NULL
)	NULL
.	NULL

Repetitive	NULL
and	NULL
systemic	NULL
(	NULL
3	NULL
x	NULL
i.p	NULL
.	NULL
)	NULL

injections	NULL
of	NULL
high	NULL
doses	NULL
of	NULL
peptide	NULL
derived	NULL
from	NULL
LCMV-induced	NULL
tolerance	NULL
of	NULL
LCMV	NULL
-specific	NULL
CTL	NULL
.	NULL

Local	NULL
s.c.	NULL
injections	NULL
of	NULL
this	NULL
peptide	NULL
protected	NULL
mice	NULL
against	NULL
LCMV	NULL
infection	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
Kear-ney	NULL
et	NULL
al	NULL
.	NULL

(	NULL
31	NULL
)	NULL
have	NULL
shown	NULL
in	NULL
an	NULL
adoptive	NULL
transfer	NULL
system	NULL
that	NULL
TCR-transgenic	NULL
T	NULL
cells	NULL
are	NULL
tolerized	NULL
by	NULL
systemic	NULL
intravenous	NULL
or	NULL
i.p	NULL
.	NULL

injections	NULL
of	NULL
the	NULL
specific	NULL
peptide	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
same	NULL
T	NULL
cells	NULL
are	NULL
stimulated	NULL
after	NULL
s.c.	NULL
injection	NULL
of	NULL
the	NULL
peptide	NULL
emulsified	NULL
in	NULL
complete	NULL
Freund	NULL
's	NULL
adjuvants	NULL
.	NULL

They	NULL
hypothesize	NULL
that	NULL
complete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
not	NULL
only	NULL
functions	NULL
as	NULL
a	NULL
depot	NULL
that	NULL
mediates	NULL
a	NULL
relatively	NULL
slow	NULL
release	NULL
of	NULL
peptide	NULL
for	NULL
a	NULL
prolonged	NULL
time	NULL
period	NULL
,	NULL
but	NULL
would	NULL
also	NULL
activate	NULL
the	NULL
local	NULL
antigen	NULL
presenting	NULL
cells	NULL
because	NULL
it	NULL
contains	NULL
Mycobacterial	NULL
compo-nents	NULL
.	NULL

We	NULL
used	NULL
as	NULL
an	NULL
adjuvant	NULL
IFA	NULL
.	NULL

IFA	NULL
functions	NULL
as	NULL
a	NULL
noninflammatory	NULL
vehicle	NULL
because	NULL
it	NULL
lacks	NULL
bacterial	NULL
compo-nents	NULL
.	NULL

Nonetheless	NULL
,	NULL
s.c	NULL
administration	NULL
of	NULL
the	NULL
AdSE1A	NULL
peptide	NULL
in	NULL
complete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
induces	NULL
,	NULL
in	NULL
the	NULL
AdS5E1A-tumor	NULL
model	NULL
,	NULL
the	NULL
same	NULL
effects	NULL
as	NULL
injection	NULL
of	NULL
the	NULL
peptide	NULL
in	NULL
IFA	NULL
.	NULL

The	NULL
rapid	NULL
,	NULL
peptide-specific	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
B6	NULL
mice	NULL
to	NULL
control	NULL
the	NULL
outgrowth	NULL
of	NULL
AdSE1A-expressing	NULL
tumors	NULL
is	NULL
,	NULL
like	NULL
immunization	NULL
in	NULL
IFA	NULL
,	NULL
associated	NULL
with	NULL
severe	NULL
lung	NULL
congestion	NULL
when	NULL
given	NULL
on	NULL
the	NULL
same	NULL
day	NULL
as	NULL
an	NULL
adoptively	NULL
transferred	NULL
AdSE1A-specific	NULL
CTL	NULL
clone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
T-cell	NULL
tolerance	NULL
has	NULL
also	NULL
been	NULL
described	NULL
in	NULL
other	NULL
TCR	NULL
transgenic	NULL
mouse	NULL
models	NULL
.	NULL

Continuous	NULL
exposure	NULL
to	NULL
a	NULL
high	NULL
dose	NULL
(	NULL
100-150	NULL
ug	NULL
)	NULL
of	NULL
peptide	NULL
366-374	NULL
deduced	NULL
from	NULL
the	NULL
nucleo-	NULL
protein	NULL
of	NULL
influenza	NULL
virus	NULL
of	NULL
TCR	NULL
transgenic	NULL
mice	NULL
expressing	NULL
a	NULL
TCR	NULL
with	NULL
a	NULL
specificity	NULL
for	NULL
this	NULL
peptide	NULL
resulted	NULL
in	NULL
a	NULL
depletion	NULL
of	NULL
most	NULL
peripheral	NULL
CD8	NULL
#	NULL
*	NULL
T	NULL
cells	NULL
bearing	NULL
the	NULL
transgenic	NULL
TCR	NULL
(	NULL
28	NULL
)	NULL
.	NULL

This	NULL
depletion	NULL
appeared	NULL
to	NULL
be	NULL
the	NULL
result	NULL
of	NULL
thymic	NULL
clonal	NULL
elimination	NULL
as	NULL
well	NULL
as	NULL
peripheral	NULL
loss	NULL
of	NULL
reactive	NULL
T	NULL
cells	NULL
.	NULL

Peripheral	NULL
T	NULL
cells	NULL
in	NULL
mice	NULL
transgenic	NULL
for	NULL
TCR	NULL
reactive	NULL
with	NULL
a	NULL
simian	NULL
virus	NULL
40-encoded	NULL
peptide	NULL
or	NULL
a	NULL
pigeon	NULL
cytochrome	NULL
c	NULL
peptide	NULL
are	NULL
depleted	NULL
in	NULL
vivo	NULL
by	NULL
repeated	NULL
injection	NULL
of	NULL
high	NULL
doses	NULL
(	NULL
100	NULL
ug	NULL
peptide	NULL
injected	NULL
i.p	NULL
.	NULL

,	NULL
three	NULL
times	NULL
)	NULL
of	NULL
the	NULL
specific	NULL
peptides	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

In	NULL
all	NULL
these	NULL
models	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
models	NULL
where	NULL
T-cell	NULL
responses	NULL
are	NULL
induced	NULL
,	NULL
repetitive	NULL
and	NULL
systemic	NULL
injections	NULL
of	NULL
relatively	NULL
high	NULL
doses	NULL
of	NULL
antigenic	NULL
peptides	NULL
are	NULL
given	NULL
.	NULL

We	NULL
now	NULL
describe	NULL
that	NULL
a	NULL
single	NULL
s.c.	NULL
injection	NULL
of	NULL
a	NULL
much	NULL
lower	NULL
amount	NULL
of	NULL
peptide	NULL
in	NULL
IFA	NULL
can	NULL
induce	NULL
T-cell	NULL
unrespon-siveness	NULL
,	NULL
leading	NULL
to	NULL
an	NULL
enhanced	NULL
outgrowth	NULL
of	NULL
tumors	NULL
in	NULL
normal	NULL
immunocompetent	NULL
animals	NULL
.	NULL

The	NULL
reasons	NULL
why	NULL
one	NULL
peptide	NULL
induces	NULL
protective	NULL
T-cell-mediated	NULL
immunity	NULL
and	NULL
another	NULL
T-cell	NULL
tolerance	NULL
when	NULL
administered	NULL
at	NULL
comparable	NULL
concentrations	NULL
via	NULL
the	NULL
same	NULL
vaccination	NULL
scheme	NULL
are	NULL
intriguing	NULL
.	NULL

A	NULL
possible	NULL
explanation	NULL
is	NULL
that	NULL
peptides	NULL
administered	NULL
s.c.	NULL
in	NULL
IFA	NULL
eliciting	NULL
protective	NULL
immune	NULL
responses	NULL
,	NULL
such	NULL
as	NULL
the	NULL
HPV16	NULL
peptide	NULL
are	NULL
retained	NULL
locally	NULL
,	NULL
forming	NULL
a	NULL
gradient	NULL
of	NULL
antigen	NULL
.	NULL

The	NULL
AdSE1A	NULL
peptide	NULL
diffuses	NULL
rapidly	NULL
throughout	NULL
the	NULL
body	NULL
,	NULL
instigating	NULL
downregula-tion	NULL
of	NULL
the	NULL
Ad5E1A-specific	NULL
CTL	NULL
response	NULL
.	NULL

Systemic	NULL
distribution	NULL
might	NULL
lead	NULL
to	NULL
massive	NULL
activation	NULL
of	NULL
peptide-specific	NULL
CTL	NULL
,	NULL
that	NULL
,	NULL
especially	NULL
if	NULL
associated	NULL
with	NULL
inappropriate	NULL
costimulation	NULL
,	NULL
may	NULL
result	NULL
in	NULL
the	NULL
clonal	NULL
exhausting	NULL
of	NULL
these	NULL
CTL	NULL
.	NULL

By	NULL
analogy	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
an	NULL
LCMV	NULL
model	NULL
that	NULL
virus	NULL
spread	NULL
and	NULL
CTL	NULL
induction/exhaustion	NULL
are	NULL
closely	NULL
linked	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Infection	NULL
with	NULL
LCMV-DOCILE	NULL
,	NULL
a	NULL
virus	NULL
isolate	NULL
that	NULL
replicates	NULL
rapidly	NULL
and	NULL
widely	NULL
when	NULL
injected	NULL
in-	NULL
mice	NULL
,	NULL
induced	NULL
LCMV	NULL
-specific	NULL
CTL	NULL
tolerance	NULL
,	NULL
whereas	NULL
infection	NULL
with	NULL
LCMV-WE	NULL
,	NULL
an	NULL
isolate	NULL
that	NULL
replicates	NULL
more	NULL
slowly	NULL
,	NULL
induced	NULL
long-lasting	NULL
LCMV-specific	NULL
CTL	NULL
memory	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
it	NULL
is	NULL
remarkable	NULL
to	NULL
note	NULL
that	NULL
administration	NULL
of	NULL
the	NULL
HPV16	NULL
E745_5	NULL
;	NULL
peptide	NULL
on	NULL
the	NULL
same	NULL
day	NULL
as	NULL
intravenous	NULL
injection	NULL
of	NULL
a	NULL
HPV16	NULL
E74	NULL
$	NULL
_s7-specific	NULL
CTL	NULL
clone	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
severe	NULL
lung	NULL
congestion	NULL
(	NULL
R.E.M.T	NULL
.	NULL

,	NULL
M.C.W	NULL
.	NULL

Feltkamp	NULL
,	NULL
M.P.M	NULL
.	NULL

Vierboom	NULL
,	NULL
C.J.M.M	NULL
.	NULL

,	NULL
and	NULL
W.M.K	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
HPV16	NULL
E7-peptide	NULL
is	NULL
retained	NULL
locally	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
functional	NULL
T-cell-specific	NULL
tolerance	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
low	NULL
doses	NULL
of	NULL
peptide	NULL
administered	NULL
locally	NULL
is	NULL
not	NULL
only	NULL
important	NULL
for	NULL
the	NULL
development	NULL
of	NULL
safe	NULL
peptide-based	NULL
anti-tumor	NULL
and	NULL
anti-virus	NULL
vaccines	NULL
,	NULL
but	NULL
may	NULL
also	NULL
have	NULL
implications	NULL
for	NULL
the	NULL
design	NULL
of	NULL
therapeutic	NULL
protocols	NULL
for	NULL
CTL-mediated	NULL
autoimmune	NULL
diseases	NULL
and	NULL
harmful	NULL
T-cell	NULL
responses	NULL
against	NULL
allogeneic	NULL
organ	NULL
transplants	NULL
.	NULL

Modification	NULL
of	NULL
T-cell-mediated	NULL
autoimmune	NULL
diseases	NULL
and	NULL
immunopathologies	NULL
by	NULL
peptides	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
7860	NULL
Immunology	NULL
:	NULL
Toes	NULL
et	NULL
al	NULL
.	NULL

experimental	NULL
autoimmune	NULL
encephalomyelitis	NULL
and	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
T-cell	NULL
recognition	NULL
of	NULL
house	NULL
dust	NULL
mite	NULL
allergens	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
oral	NULL
administration	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex-derived	NULL
allopeptides	NULL
can	NULL
induce	NULL
donor-specific	NULL
T-cell	NULL
tolerance	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

By	NULL
specifically	NULL
tolerizing	NULL
harmful	NULL
CTL	NULL
through	NULL
injections	NULL
with	NULL
low	NULL
doses	NULL
of	NULL
peptides	NULL
it	NULL
might	NULL
be	NULL
possible	NULL
to	NULL
prevent	NULL
or	NULL
temper	NULL
CTL-dependent	NULL
diseases	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
earlier	NULL
reports	NULL
describing	NULL
induction	NULL
of	NULL
T-cell-mediated	NULL
protection	NULL
against	NULL
a	NULL
subsequent	NULL
challenge	NULL
of	NULL
virus	NULL
or	NULL
tumor	NULL
cells	NULL
following	NULL
a	NULL
single	NULL
s.c.	NULL
injection	NULL
of	NULL
synthetic	NULL
peptide	NULL
in	NULL
adjuvant	NULL
,	NULL
we	NULL
now	NULL
describe	NULL
that	NULL
such	NULL
vaccination	NULL
schemes	NULL
can	NULL
also	NULL
lead	NULL
to	NULL
a	NULL
functional	NULL
deletion	NULL
of	NULL
tumor-specific	NULL
CTL	NULL
.	NULL

Epitope	NULL
delivery	NULL
by	NULL
vaccination	NULL
with	NULL
infectious	NULL
adenovirus	NULL
type	NULL
5	NULL
was	NULL
associated	NULL
with	NULL
protection	NULL
and	NULL
CTL	NULL
memory	NULL
rather	NULL
than	NULL
tolerance	NULL
and	NULL
tumor	NULL
outgrowth	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
peptide-based	NULL
vaccines	NULL
must	NULL
be	NULL
employed	NULL
with	NULL
caution	NULL
in	NULL
a	NULL
human	NULL
setting	NULL
,	NULL
because	NULL
immunization	NULL
with	NULL
tumor	NULL
specific	NULL
peptides	NULL
might	NULL
lead	NULL
to	NULL
a	NULL
diminished	NULL
rather	NULL
than	NULL
a	NULL
protective	NULL
immune	NULL
response	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
AdSE1A-tumor	NULL
system	NULL
only	NULL
a	NULL
single	NULL
viral	NULL
antigen	NULL
is	NULL
expressed	NULL
.	NULL

In	NULL
naturally	NULL
occurring	NULL
tumors	NULL
there	NULL
may	NULL
be	NULL
a	NULL
larger	NULL
number	NULL
of	NULL
relevant	NULL
T-cell	NULL
epitopes	NULL
and	NULL
tolerance	NULL
to	NULL
a	NULL
single	NULL
epitope	NULL
may	NULL
not	NULL
have	NULL
the	NULL
same	NULL
dramatic	NULL
consequences	NULL
as	NULL
observed	NULL
in	NULL
the	NULL
AdSE1A-tumor	NULL
system	NULL
.	NULL

Nonetheless	NULL
,	NULL
candidate	NULL
peptides	NULL
for	NULL
human	NULL
anti-virus	NULL
and	NULL
anti-cancer	NULL
vaccines	NULL
should	NULL
be	NULL
tested	NULL
for	NULL
their	NULL
immunizing	NULL
or	NULL
tolerizing	NULL
properties	NULL
in	NULL
vivo	NULL
in	NULL
vaccination	NULL
experiments	NULL
in	NULL
human	NULL
leucocyte	NULL
antigen-transgenic	NULL
mice	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
investigation	NULL
of	NULL
immunizing	NULL
and	NULL
tolerogenic	NULL
modes	NULL
of	NULL
peptide	NULL
delivery	NULL
deserves	NULL
detailed	NULL
attention	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
J.	NULL
W.	NULL
Drijffout	NULL
for	NULL
synthesizing	NULL
peptides	NULL
,	NULL
Dr.	NULL
P.	NULL
Krimpenfort	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
TCR-transgenic	NULL
mice	NULL
,	NULL
Drs	NULL
.	NULL

T.	NULL
Ottenhoff	NULL
and	NULL
S.	NULL
P.	NULL
Schoenberger	NULL
for	NULL
critically	NULL
reading	NULL
the	NULL
manuscript	NULL
,	NULL
Dr.	NULL
J	NULL
.	NULL

D'Amaro	NULL
for	NULL
statistical	NULL
analysis	NULL
,	NULL
and	NULL
Dr.	NULL
R.	NULL
Hoeben	NULL
for	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
Ad5ts149	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Dutch	NULL
Cancer	NULL
Foundation	NULL
,	NULL
Grants	NULL
RUL	NULL
90-23	NULL
and	NULL
93-588	NULL
.	NULL

1	NULL
.	NULL

Greenberg	NULL
,	NULL
P.	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

49	NULL
,	NULL
281-335	NULL
.	NULL

2	NULL
.	NULL

Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

58	NULL
,	NULL
143-175	NULL
.	NULL

3	NULL
.	NULL

Townsend	NULL
,	NULL
A.	NULL
R.	NULL
M.	NULL
,	NULL
Rothbard	NULL
,	NULL
J.	NULL
,	NULL
Gotch	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Bahadur	NULL
,	NULL
G.	NULL
,	NULL
Wraith	NULL
,	NULL
D.	NULL
&	NULL
McMichael	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cell	NULL
44	NULL
,	NULL
959-968	NULL
.	NULL

4	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
Offringa	NULL
,	NULL
R.	NULL
,	NULL
Feltkamp	NULL
,	NULL
M.C	NULL
.	NULL

W.	NULL
,	NULL
Visseren	NULL
,	NULL
M.	NULL
J.	NULL
W.	NULL
,	NULL
Schoenberger	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
&	NULL
Kast	NULL
,	NULL
W.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Behring	NULL
Inst	NULL
.	NULL

Mitt	NULL
.	NULL

94	NULL
,	NULL
72-86	NULL
.	NULL

5	NULL
.	NULL

Kast	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Roux	NULL
,	NULL
L.	NULL
,	NULL
Curren	NULL
,	NULL
J.	NULL
,	NULL
Blom	NULL
,	NULL
H.	NULL
J.	NULL
J.	NULL
,	NULL
Voordouw	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Meloen	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Kolakofsky	NULL
,	NULL
D.	NULL
&	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
2283-2287	NULL
.	NULL

6	NULL
.	NULL

Schulz	NULL
,	NULL
M.	NULL
,	NULL
Zinkernage	NULL
}	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Hengartner	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
991-993	NULL
.	NULL

7	NULL
.	NULL

-	NULL
Feltkamp	NULL
,	NULL
M.	NULL
C.	NULL
W.	NULL
,	NULL
Smits	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Vierboom	NULL
,	NULL
M.	NULL
P.	NULL
M.	NULL
,	NULL
Minnaar	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
de	NULL
Jongh	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Drijfhout	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
ter	NULL
Schegget	NULL
,	NULL
J.	NULL
,	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
&	NULL
Kast	NULL
,	NULL
W.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23	NULL
,	NULL
2242-2249	NULL
.	NULL

8	NULL
.	NULL

Feltkamp	NULL
,	NULL
M.	NULL
C.	NULL
W.	NULL
,	NULL
Vreugdenhil	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Vierboom	NULL
,	NULL
M.	NULL
P.	NULL
M.	NULL
,	NULL
Ras	NULL
,	NULL
E.	NULL
,	NULL
van	NULL
der	NULL
Burg	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
ter	NULL
Schegget	NULL
,	NULL
J.	NULL
,	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
&	NULL
Kast	NULL
,	NULL
W.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
2638-2642	NULL
.	NULL

9	NULL
.	NULL

Minev	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
McFarland	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Spiess	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Rosenberg	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

&	NULL
Restifo	NULL
,	NULL
N.	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

54	NULL
,	NULL
4155-4161	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Ressing	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Sette	NULL
,	NULL
A.	NULL
,	NULL
Brandt	NULL
,	NULL
R.	NULL
M.	NULL
P.	NULL
,	NULL
Ruppert	NULL
,	NULL
J.	NULL
,	NULL
Went-worth	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Hartman	NULL
,	NULL
M.	NULL
,	NULL
Oseroff	NULL
,	NULL
C.	NULL
,	NULL
Grey	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
&	NULL
Kast	NULL
,	NULL
W.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
5934-5943	NULL
.	NULL

Vitiello	NULL
,	NULL
A.	NULL
,	NULL
Ishioka	NULL
,	NULL
G.	NULL
,	NULL
Grey	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Rose	NULL
,	NULL
R.	NULL
,	NULL
Farness	NULL
,	NULL
P.	NULL
,	NULL
Lafond	NULL
,	NULL
R.	NULL
,	NULL
Yuan	NULL
,	NULL
L.	NULL
,	NULL
Chisari	NULL
,	NULL
F.	NULL
V.	NULL
,	NULL
Furze	NULL
,	NULL
J.	NULL
,	NULL
Bartholomeusz	NULL
,	NULL
R.	NULL
&	NULL
Chesnut	NULL
,	NULL
R.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

95	NULL
,	NULL
341-349	NULL
.	NULL

Aichele	NULL
,	NULL
P.	NULL
,	NULL
Kyburz	NULL
,	NULL
D.	NULL
,	NULL
Ohashi	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Odermatt	NULL
,	NULL
B.	NULL
,	NULL
Zinkernagel	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Hengartner	NULL
,	NULL
H.	NULL
&	NULL
Pircher	NULL
,	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
USA	NULL
91	NULL
,	NULL
444-448	NULL
.	NULL

Aichele	NULL
,	NULL
P.	NULL
,	NULL
Brduscha-Riem	NULL
,	NULL
K.	NULL
,	NULL
Zinkernagel	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Hengartner	NULL
,	NULL
H.	NULL
&	NULL
Pircher	NULL
,	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
,	NULL
261-266	NULL
.	NULL

Kast	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Offringa	NULL
,	NULL
R.	NULL
,	NULL
Peters	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Voordouw	NULL
,	NULL
A.	NULL
,	NULL
Meloen	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
A.J	NULL
.	NULL

&	NULL
Melief	NULL
,	NULL
C.J	NULL
.	NULL

M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
603-615	NULL
.	NULL

Greaves	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Wilson	NULL
,	NULL
F.	NULL
D.	NULL
,	NULL
Lang	NULL
,	NULL
G.	NULL
&	NULL
Kioussis	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
979-986	NULL
.	NULL

Jochemsen	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Bos	NULL
,	NULL
J.	NULL
L.	NULL
&	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

5	NULL
,	NULL
2923-2927	NULL
.	NULL

Capon	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Chen	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
Tevinson	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Seeburg	NULL
,	NULL
P.	NULL
H.	NULL
&	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1982	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
302	NULL
,	NULL
33-37	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
Offringa	NULL
,	NULL
R.	NULL
,	NULL
Blom	NULL
,	NULL
R.	NULL
J.	NULL
J.	NULL
,	NULL
Brandt	NULL
,	NULL
R.	NULL
M.	NULL
P.	NULL
,	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
&	NULL
Kast	NULL
,	NULL
W.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
3396-3405	NULL
.	NULL

Gausepohl	NULL
,	NULL
H.	NULL
,	NULL
Kraft	NULL
,	NULL
M.	NULL
,	NULL
Boulin	NULL
,	NULL
Ch	NULL
.	NULL

&	NULL
Frank	NULL
,	NULL
R.	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
in	NULL
Proceedings	NULL
of	NULL
the	NULL
11th	NULL
American	NULL
Peptide	NULL
Symposium	NULL
,	NULL
eds	NULL
.	NULL

Rivier	NULL
,	NULL
J.	NULL
E.	NULL
&	NULL
Manshall	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
ESCOM	NULL
,	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
,	NULL
p.	NULL
1003	NULL
.	NULL

Sharrock	NULL
,	NULL
C.	NULL
E.	NULL
M.	NULL
,	NULL
Kaminski	NULL
,	NULL
E.	NULL
&	NULL
Man	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
11	NULL
,	NULL
281-286	NULL
.	NULL

Strybosch	NULL
,	NULL
L.	NULL
W.	NULL
G.	NULL
,	NULL
Buurman	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Does	NULL
,	NULL
R.	NULL
J.	NULL
M.	NULL
,	NULL
Zinken	NULL
,	NULL
P.	NULL
H.	NULL
&	NULL
Groenewegen	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
97	NULL
,	NULL
133-140	NULL
.	NULL

Kast	NULL
,	NULL
W.	NULL
M.	NULL
&	NULL
Melief	NULL
C.	NULL
J.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
(	NULL
Suppl	NULL
.	NULL
)	NULL

6	NULL
,	NULL
90-94	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
Ertl	NULL
,	NULL
H.C.	NULL
J	NULL
.	NULL

&	NULL
Wilson	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
433-442	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
Li	NULL
,	NULL
Q.	NULL
,	NULL
Ertl	NULL
,	NULL
H.	NULL
C.	NULL
J	NULL
.	NULL

&	NULL
Wilson	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
2004-2015	NULL
.	NULL

Dai	NULL
,	NULL
Y.	NULL
,	NULL
Schwarz	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Gu	NULL
,	NULL
D.	NULL
,	NULL
Zhang	NULL
,	NULL
W.-W	NULL
,	NULL
Sarvetnick	NULL
,	NULL
N.	NULL
&	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
,	NULL
1401-1405	NULL
.	NULL

Ensinger	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Ginsberg	NULL
,	NULL
H.	NULL
S.	NULL
(	NULL
1972	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

10	NULL
,	NULL
328-339	NULL
.	NULL

Rheinholdsson-Ljunggren	NULL
,	NULL
G.	NULL
,	NULL
Ramqvist	NULL
,	NULL
T.	NULL
,	NULL
Ahrlund-Richter	NULL
,	NULL
L.	NULL
&	NULL
Dalianis	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
50	NULL
,	NULL
142-146	NULL
.	NULL

Mamalaki	NULL
,	NULL
C.	NULL
,	NULL
Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
Corbella	NULL
,	NULL
P.	NULL
,	NULL
Chandler	NULL
,	NULL
P.	NULL
,	NULL
Simpson	NULL
,	NULL
E.	NULL
&	NULL
Kioussis	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
1285-1292	NULL
.	NULL

Huang	NULL
,	NULL
L.	NULL
,	NULL
Soldevilla	NULL
,	NULL
G.	NULL
,	NULL
Leeker	NULL
,	NULL
M.	NULL
,	NULL
Flavell	NULL
,	NULL
R.	NULL
&	NULL
Crispe	NULL
,	NULL
I.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
741-749	NULL
.	NULL

Singer	NULL
,	NULL
G.	NULL
G.	NULL
&	NULL
Abbas	NULL
,	NULL
A.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
366-371	NULL
.	NULL

Kearney	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
Papa	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Loh	NULL
,	NULL
D.	NULL
Y	NULL
.	NULL

&	NULL
Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
327-339	NULL
.	NULL

Zinkernagel	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Moskophidis	NULL
,	NULL
D.	NULL
,	NULL
Kiindig	NULL
,	NULL
T.	NULL
,	NULL
Oehen	NULL
,	NULL
S.	NULL
,	NULL
Pircher	NULL
,	NULL
H.	NULL
&	NULL
Hengartner	NULL
,	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

131	NULL
,	NULL
199-223	NULL
.	NULL

Smilek	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Wraith	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Hodgkinson	NULL
,	NULL
S.	NULL
,	NULL
Dwivedy	NULL
,	NULL
S.	NULL
,	NULL
Stein-man	NULL
,	NULL
L.	NULL
&	NULL
McDevitt	NULL
,	NULL
H.	NULL
O	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
9633-9637	NULL
.	NULL

Hoyne	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
O'Heir	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Wraith	NULL
,	NULL
D.C.	NULL
,	NULL
Thomas	NULL
,	NULL
W.	NULL
R.	NULL
&	NULL
Lamb	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
1783-1788	NULL
.	NULL

Sayegh	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Khoury	NULL
,	NULL
S.	NULL
J.	NULL
;	NULL
Hancock	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Weiner	NULL
,	NULL
H.	NULL
L.	NULL
&	NULL
Carpenter	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
7762-7766	NULL
.	NULL

Nisco	NULL
,	NULL
S.	NULL
,	NULL
Vriens	NULL
,	NULL
P.	NULL
,	NULL
Hoyt	NULL
,	NULL
G.	NULL
,	NULL
Lyu	NULL
,	NULL
S.-C	NULL
,	NULL
Farfan	NULL
,	NULL
F.	NULL
,	NULL
Pouletty	NULL
,	NULL
P.	NULL
,	NULL
Krensky	NULL
,	NULL
A.	NULL
M.	NULL
&	NULL
Clayberger	NULL
,	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
3786-3792	NULL
.	NULL

